#BEGIN_DRUGCARD DB00786

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Marimastat [Usan]

# CAS_Registry_Number:
154039-60-8

# ChEBI_ID:
50662

# Chemical_Formula:
C15H29N3O5

# Chemical_IUPAC_Name:
(2S,3R)-N-[(1S)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-N',2-dihydroxy-3-(2-methylpropyl)butanediamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.

# Dosage_Forms:
Not Available

# Drug_Category:
Antineoplastic Agents
Enzyme Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.4

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Marimastat

# HET_ID:
097

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1

# InChI_Key:
InChIKey=OCSMOTCMPXTDND-OUAUKWLOSA-N

# Indication:
For the treatment of various cancers

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
786

# Mechanism_Of_Action:
Marimastat is a broad spectrum matrix metalloprotease inhibitor. It mimics the peptide structure of natural MMP substrates and binds to matrix metalloproteases, thereby preventing the degradation of the basement membrane by these proteases. This antiprotease action prevents the migration of endothelial cells needed to form new blood vessels. Inhibition of MMPs also prevents the entry and exit of tumor cells into existing blood cells, thereby preventing metastasis.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
331.4079

# Molecular_Weight_Mono:
331.210721053

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1EZF

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164748329

# Pharmacology:
Used in the treatment of cancer, it is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.

# Predicted_LogP_Hydrophobicity:
0.41

# Predicted_LogS:
-2

# Predicted_Water_Solubility:
3.38e+00 g/l

# Primary_Accession_No:
DB00786

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
119031

# PubChem_Substance_ID:
46505547

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00559

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:38 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Marimastat

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Cytoplasmic

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
MMP13

# Drug_Target_10_GenBank_ID_Gene:
X75308

# Drug_Target_10_GenBank_ID_Protein:
516386

# Drug_Target_10_GeneCard_ID:
MMP13

# Drug_Target_10_Gene_Name:
MMP13

# Drug_Target_10_Gene_Sequence:
>1416 bp
ATGCATCCAGGGGTCCTGGCTGCCTTCCTCTTCTTGAGCTGGACTCATTGTCGGGCCCTG
CCCCTTCCCAGTGGTGGTGATGAAGATGATTTGTCTGAGGAAGACCTCCAGTTTGCAGAG
CGCTACCTGAGATCATACTACCATCCTACAAATCTCGCGGGAATCCTGAAGGAGAATGCA
GCAAGCTCCATGACTGAGAGGCTCCGAGAAATGCAGTCTTTCTTCGGCTTAGAGGTGACT
GGCAAACTTGACGATAACACCTTAGATGTCATGAAAAAGCCAAGATGCGGGGTTCCTGAT
GTGGGTGAATACAATGTTTTCCCTCGAACTCTTAAATGGTCCAAAATGAATTTAACCTAC
AGAATTGTGAATTACACCCCTGATATGACTCATTCTGAAGTCGAAAAGGCATTCAAAAAA
GCCTTCAAAGTTTGGTCCGATGTAACTCCTCTGAATTTTACCAGACTTCACGATGGCATT
GCTGACATCATGATCTCTTTTGGAATTAAGGAGCATGGCGACTTCTACCCATTTGATGGG
CCCTCTGGCCTGCTGGCTCATGCTTTTCCTCCTGGGCCAAATTATGGAGGAGATGCCCAT
TTTGATGATGATGAAACCTGGACAAGTAGTTCCAAAGGCTACAACTTGTTTCTTGTTGCT
GCGCATGAGTTCGGCCACTCCTTAGGTCTTGACCACTCCAAGGACCCTGGAGCACTCATG
TTTCCTATCTACACCTACACCGGCAAAAGCCACTTTATGCTTCCTGATGACGATGTACAA
GGGATCCAGTCTCTCTATGGTCCAGGAGATGAAGACCCCAACCCTAAACATCCAAAAACG
CCAGACAAATGTGACCCTTCCTTATCCCTTGATGCCATTACCAGTCTCCGAGGAGAAACA
ATGATCTTTAAAGACAGATTCTTCTGGCGCCTGCATCCTCAGCAGGTTGATGCGGAGCTG
TTTTTAACGAAATCATTTTGGCCAGAACTTCCCAACCGTATTGATGCTGCATATGAGCAC
CCTTCTCATGACCTCATCTTCATCTTCAGAGGTAGAAAATTTTGGGCTCTTAATGGTTAT
GACATTCTGGAAGGTTATCCCAAAAAAATATCTGAACTGGGTCTTCCAAAAGAAGTTAAG
AAGATAAGTGCAGCTGTTCACTTTGAGGATACAGGCAAGACTCTCCTGTTCTCAGGAAAC
CAGGTCTGGAGATATGATGATACTAACCATATTATGGATAAAGACTATCCGAGACTAATA
GAAGAAGACTTCCCAGGAATTGGTGATAAAGTAGATGCTGTCTATGAGAAAAATGGTTAT
ATCTATTTTTTCAACGGACCCATACAGTTTGAATACAGCATCTGGAGTAACCGTATTGTT
CGCGTCATGCCAGCAAATTCCATTTTGTGGTGTTAA

# Drug_Target_10_General_Function:
Involved in protease activity

# Drug_Target_10_General_References:
8207000	Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994 Jun 17;269(24):16766-73.
8969305	Gomis-Ruth FX, Gohlke U, Betz M, Knauper V, Murphy G, Lopez-Otin C, Bode W: The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain. J Mol Biol. 1996 Dec 6;264(3):556-66.
9562863	Willmroth F, Peter HH, Conca W: A matrix metalloproteinase gene expressed in human T lymphocytes is identical with collagenase 3 from breast carcinomas. Immunobiology. 1998 Feb;198(4):375-84.

# Drug_Target_10_HGNC_ID:
HGNC:7159

# Drug_Target_10_HPRD_ID:
02522

# Drug_Target_10_ID:
1330

# Drug_Target_10_Locus:
11q22.3

# Drug_Target_10_Molecular_Weight:
53820

# Drug_Target_10_Name:
Collagenase 3

# Drug_Target_10_Number_of_Residues:
471

# Drug_Target_10_PDB_ID:
Not Available

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_10_Protein_Sequence:
>Collagenase 3 precursor
MHPGVLAAFLFLSWTHCRALPLPSGGDEDDLSEEDLQFAERYLRSYYHPTNLAGILKENA
ASSMTERLREMQSFFGLEVTGKLDDNTLDVMKKPRCGVPDVGEYNVFPRTLKWSKMNLTY
RIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDG
PSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALM
FPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPNPKHPKTPDKCDPSLSLDAITSLRGET
MIFKDRFFWRLHPQQVDAELFLTKSFWPELPNRIDAAYEHPSHDLIFIFRGRKFWALNGY
DILEGYPKKISELGLPKEVKKISAAVHFEDTGKTLLFSGNQVWRYDDTNHIMDKDYPRLI
EEDFPGIGDKVDAVYEKNGYIYFFNGPIQFEYSIWSNRIVRVMPANSILWC

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
1-19

# Drug_Target_10_Specific_Function:
Degrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process

# Drug_Target_10_SwissProt_ID:
P45452

# Drug_Target_10_SwissProt_Name:
MMP13_HUMAN

# Drug_Target_10_Synonyms:
Collagenase 3 precursor
EC 3.4.24.-
MMP-13
Matrix metalloproteinase-13

# Drug_Target_10_Theoretical_pI:
5.31

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Membrane

# Drug_Target_11_Chromosome_Location:
1

# Drug_Target_11_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
D26512

# Drug_Target_11_GenBank_ID_Protein:
793763

# Drug_Target_11_GeneCard_ID:
MMP14

# Drug_Target_11_Gene_Name:
MMP14

# Drug_Target_11_Gene_Sequence:
>1749 bp
ATGTCTCCCGCCCCAAGACCCTCCCGTTGTCTCCTGCTCCCCCTGCTCACGCTCGGCACC
GCGCTCGCCTCCCTCGGCTCGGCCCAAAGCAGCAGCTTCAGCCCCGAAGCCTGGCTACAG
CAATATGGCTACCTGCCTCCCGGGGACCTACGTACCCACACACAGCGCTCACCCCAGTCA
CTCTCAGCGGCCATCGCTGCCATGCAGAAGTTTTACGGCTTGCAAGTAACAGGCAAAGCT
GATGCAGACACCATGAAGGCCATGAGGCGCCCCCGATGTGGTGTTCCAGACAAGTTTGGG
GCTGAGATCAAGGCCAATGTTCGAAGGAAGCGCTACGCCATCCAGGGTCTCAAATGGCAA
CATAATGAAATTACTTTCTGCATCCAGAATTACACCCCCAAGGTGGGCGAGTATGCCACA
TACGAGGCCATTCGCAAGGCGTTCCGCGTGTGGGAGAGTGCCACACCACTGCGCTTCCGC
GAGGTGCCCTATGCCTACATCCGTGAGGGCCATGAGAAGCAGGCCGACATCATGATCTTC
TTTGCCGAGGGCTTCCATGGCGACAGCACGCCCTTCGATGGTGAGGGCGGCTTCCTGGCC
CATGCCTACTTCCCAGGGCCCAACATTGGAGGAGACACCCACTTTGACTCTGCCGAGCCT
TGGACTGTCAGGAATGAGGATCTGAATGGAAATGACATCTTCCTGGTGGCTGTGCACGAG
CTGGGCCATGCCCTGGGGCTCGAGCATTCCAGTGACCCCTCGGCCATCATGGCACCCTTT
TACCAGTGGATGGACACGGAGAATTTTGTGCTTCCCGATGATGACCGCCGGGGCATCCAG
CAACTTTATGGGGGTGAGTCAGGGTTCCCCACCAAGATGCCCCCTCAACCCAGGACTACC
TCCCGGCCTTCTGTTCCTGATAAACCCAAAAACCCCACCTATGGGCCCAACATCTGTGAC
GGGAACTTTGACACCGTGGCCATGCTCCGAGGGGAGATGTTTGTCTTCAAGAAGCGCTGG
TTCTGGCGGGTGAGGAATAACCAAGTGATGGATGGATACCCAATGCCCATTGGCCAGTTC
TGGCGGGGCCTGCCTGCGTCCATCAACACTGCCTACGAGAGGAAGGATGGCAAATTCGTC
TTCTTCAAAGGAGACAAGCATTGGGTGTTTGATGAGGCGTCCCTGGAACCTGGCTACCCC
AAGCACATTAAGGAGCTGGGCCGAGGGCTGCCTACCGACAAGATTGATGCTGCTCTCTTC
TGGATGCCCAATGGAAAGACCTACTTCTTCCGTGGAAACAAGTACTACCGTTTCAACGAA
GAGCTCAGGGCAGTGGATAGCGAGTACCCCAAGAACATCAAAGTCTGGGAAGGGATCCCT
GAGTCTCCCAGAGGGTCATTCATGGGCAGCGATGAAGTCTTCACTTACTTCTACAAGGGG
AACAAATACTGGAAATTCAACAACCAGAAGCTGAAGGTAGAACCGGGCTACCCCAAGTCA
GCCCTGAGGGACTGGATGGGCTGCCCATCGGGAGGCCGGCCGGATGAGGGGACTGAGGAG
GAGACGGAGGTGATCATCATTGAGGTGGACGAGGAGGGCGGCGGGGCGGTGAGCGCGGCT
GCCGTGGTGCTGCCCGTGCTGCTGCTGCTCCTGGTGCTGGCGGTGGGCCTTGCAGTCTTC
TTCTTCAGACGCCATGGGACCCCCAGGCGACTGCTCTACTGCCAGCGTTCCCTGCTGGAC
AAGGTCTGA

# Drug_Target_11_General_Function:
Involved in calcium ion binding

# Drug_Target_11_General_References:
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
7649159	Will H, Hinzmann B: cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem. 1995 Aug 1;231(3):602-8.
7708715	Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2730-4.
7721107	Takino T, Sato H, Yamamoto E, Seiki M: Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain. Gene. 1995 Apr 3;155(2):293-8.
8015608	Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994 Jul 7;370(6484):61-5.
8706726	Lohi J, Lehti K, Westermarck J, Kahari VM, Keski-Oja J: Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem. 1996 Jul 15;239(2):239-47.
8804434	Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M: Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett. 1996 Sep 9;393(1):101-4.

# Drug_Target_11_HGNC_ID:
GNC:7160

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
6191

# Drug_Target_11_Locus:
14q11-q12

# Drug_Target_11_Molecular_Weight:
65883.4

# Drug_Target_11_Name:
Matrix metalloproteinase-14

# Drug_Target_11_Number_of_Residues:
582

# Drug_Target_11_PDB_ID:
1BUV

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_11_Protein_Sequence:
>Matrix metalloproteinase-14
MSPAPRPSRCLLLPLLTLGTALASLGSAQSSSFSPEAWLQQYGYLPPGDLRTHTQRSPQS
LSAAIAAMQKFYGLQVTGKADADTMKAMRRPRCGVPDKFGAEIKANVRRKRYAIQGLKWQ
HNEITFCIQNYTPKVGEYATYEAIRKAFRVWESATPLRFREVPYAYIREGHEKQADIMIF
FAEGFHGDSTPFDGEGGFLAHAYFPGPNIGGDTHFDSAEPWTVRNEDLNGNDIFLVAVHE
LGHALGLEHSSDPSAIMAPFYQWMDTENFVLPDDDRRGIQQLYGGESGFPTKMPPQPRTT
SRPSVPDKPKNPTYGPNICDGNFDTVAMLRGEMFVFKERWFWRVRNNQVMDGYPMPIGQF
WRGLPASINTAYERKDGKFVFFKGDKHWVFDEASLEPGYPKHIKELGRGLPTDKIDAALF
WMPNGKTYFFRGNKYYRFNEELRAVDSEYPKNIKVWEGIPESPRGSFMGSDEVFTYFYKG
NKYWKFNNQKLKVEPGYPKSALRDWMGCPSGGRPDEGTEEETEVIIIEVDEEGGGAVSAA
AVVLPVLLLLLVLAVGLAVFFFRRHGTPRRLLYCQRSLLDKV

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
1-20

# Drug_Target_11_Specific_Function:
Seems to specifically activate progelatinase A. May thus trigger invasion by tumor cells by activating progelatinase A on the tumor cell surface

# Drug_Target_11_SwissProt_ID:
P50281

# Drug_Target_11_SwissProt_Name:
MMP14_HUMAN

# Drug_Target_11_Synonyms:
MMP-14
MMP-X1
MT-MMP 1
MT1-MMP
MT1MMP
MTMMP1
Membrane-type matrix metalloproteinase 1
Membrane-type-1 matrix metalloproteinase

# Drug_Target_11_Theoretical_pI:
7.87

# Drug_Target_11_Transmembrane_Regions:
542-562

# Drug_Target_12_Cellular_Location:
Membrane

# Drug_Target_12_Chromosome_Location:
1

# Drug_Target_12_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
Z48482

# Drug_Target_12_GenBank_ID_Protein:
963056

# Drug_Target_12_GeneCard_ID:
MMP15

# Drug_Target_12_Gene_Name:
MMP15

# Drug_Target_12_Gene_Sequence:
>2010 bp
ATGGGCAGCGACCCGAGCGCGCCCGGACGGCCGGGCTGGACGGGCAGCCTCCTCGGCGAC
CGGGAGGAGGCGGCGCGGCCGCGACTGCTGCCGCTGCTCCTGGTGCTTCTGGGCTGCCTG
GGCCTTGGCGTAGCGGCCGAAGACGCGGAGGTCCATGCCGAGAACTGGCTGCGGCTTTAT
GGCTACCTGCCTCAGCCCAGCCGCCATATGTCCACCATGCGTTCCGCCCAGATCTTGGCC
TCGGCCCTTGCAGAGATGCAGCGCTTCTACGGGATCCCAGTCACCGGTGTGCTCGACGAA
GAGACCAAGGAGTGGATGAAGCGGCCCCGCTGTGGGGTGCCAGACCAGTTCGGGGTACGA
GTGAAAGCCAACCTGCGGCGGCGTCGGAAGCGCTACGCCCTCACCGGGAGGAAGTGGAAC
AACCACCATCTGACCTTTAGCATCCAGAACTACACGGAGAAGTTGGGCTGGTACCACTCG
ATGGAGGCGGTGCGCAGGGCCTTCCGCGTGTGGGAGCAGGCCACGCCCCTGGTCTTCCAG
GAGGTGCCCTATGAGGACATCCGGCTGCGGCGACAGAAGGAGGCCGACATCATGGTACTC
TTTGCCTCTGGCTTCCACGGCGACAGCTCGCCGTTTGATGGCACCGGTGGCTTTCTGGCC
CACGCCTATTTCCCTGGCCCCGGCCTAGGCGGGGACACCCATTTTGACGCAGATGAGCCC
TGGACCTTCTCCAGCACTGACCTGCATGGAAACAACCTCTTCCTGGTGGCAGTGCATGAG
CTGGGCCACGCGCTGGGGCTGGAGCACTCCAGCAACCCCAATGCCATCATGGCGCCGTTC
TACCAGTGGAAGGACGTTGACAACTTCAAGCTGCCCGAGGACGATCTCCGTGGCATCCAG
CAGCTCTACGGTACCCCAGACGGTCAGCCACAGCCTACCCAGCCTCTCCCCACTGTGACG
CCACGGCGGCCAGGCCGGCCTGACCACCGGCCGCCCCGGCCTCCCCAGCCACCACCCCCA
GGTGGGAAGCCAGAGCGGCCCCCAAAGCCGGGCCCCCCAGTCCAGCCCCGAGCCACAGAG
CGGCCCGACCAGTATGGCCCCAACATCTGCGACGGGGACTTTGACACAGTGGCCATGCTT
CGCGGGGAGATGTTCGTGTTCAAGGGCCGCTGGTTCTGGCGAGTCCGGCACAACCGCGTC
CTGGACAACTATCCCATGCCCATCGGGCACTTCTGGCGTGGTCTGCCCGGTGACATCAGT
GCTGCCTACGAGCGCCAAGACGGTCGTTTTGTCTTTTTCAAAGGTGACCGCTACTGGCTC
TTTCGAGAAGCGAACCTGGAGCCCGGCTACCCACAGCCGCTGACCAGCTATGGCCTGGGC
ATCCCCTATGACCGCATTGACACGGCCATCTGGTGGGAGCCCACAGGCCACACCTTCTTC
TTCCAAGAGGACAGGTACTGGCGCTTCAACGAGGAGACACAGCGTGGAGACCCTGGGTAC
CCCAAGCCCATCAGTGTCTGGCAGGGGATCCCTGCCTCCCCTAAAGGGGCCTTCCTGAGC
AATGACGCAGCCTACACCTACTTCTACAAGGGCACCAAATACTGGAAATTCGACAATGAG
CGCCTGCGGATGGAGCCCGGCTACCCCAAGTCCATCCTGCGGGACTTCATGGGCTGCCAG
GAGCACGTGGAGCCAGGCCCCCGATGGCCCGACGTGGCCCGGCCGCCCTTCAACCCCCAC
GGGGGTGCAGAGCCCGGGGCGGACAGCGCAGAGGGCGACGTGGGGGATGGGGATGGGGAC
TTTGGGGCCGGGGTCAACAAGGACGGGGGCAGCCGCGTGGTGGTGCAGATGGAGGAGGTG
GCACGGACGGTGAACGTGGTGATGGTGCTGGTGCCACTGCTGCTGCTGCTCTGCGTCCTG
GGCCTCACCTACGCGCTGGTGCAGATGCAGCGCAAGGGTGCGCCACGTGTCCTGCTTTAC
TGCAAGCGCTCGCTGCAGGAGTGGGTCTGA

# Drug_Target_12_General_Function:
Involved in calcium ion binding

# Drug_Target_12_General_References:
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16959974	Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.
18691976	Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell. 2008 Aug 8;31(3):438-48.
7649159	Will H, Hinzmann B: cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem. 1995 Aug 1;231(3):602-8.
9119382	Sato H, Tanaka M, Takino T, Inoue M, Seiki M: Assignment of the human genes for membrane-type-1, -2, and -3 matrix metalloproteinases (MMP14, MMP15, and MMP16) to 14q12.2, 16q12.2-q21, and 8q21, respectively, by in situ hybridization. Genomics. 1997 Feb 1;39(3):412-3.
9461298	d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G: Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem. 1997 Dec 15;250(3):751-7.

# Drug_Target_12_HGNC_ID:
GNC:7161

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
6192

# Drug_Target_12_Locus:
16q13-q21

# Drug_Target_12_Molecular_Weight:
75806.4

# Drug_Target_12_Name:
Matrix metalloproteinase-15

# Drug_Target_12_Number_of_Residues:
669

# Drug_Target_12_PDB_ID:
Not Available

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_12_Protein_Sequence:
>Matrix metalloproteinase-15
MGSDPSAPGRPGWTGSLLGDREEAARPRLLPLLLVLLGCLGLGVAAEDAEVHAENWLRLY
GYLPQPSRHMSTMRSAQILASALAEMQRFYGIPVTGVLDEETKEWMKRPRCGVPDQFGVR
VKANLRRRRKRYALTGRKWNNHHLTFSIQNYTEKLGWYHSMEAVRRAFRVWEQATPLVFQ
EVPYEDIRLRRQKEADIMVLFASGFHGDSSPFDGTGGFLAHAYFPGPGLGGDTHFDADEP
WTFSSTDLHGNNLFLVAVHELGHALGLEHSSNPNAIMAPFYQWKDVDNFKLPEDDLRGIQ
QLYGTPDGQPQPTQPLPTVTPRRPGRPDHRPPRPPQPPPPGGKPERPPKPGPPVQPRATE
RPDQYGPNICDGDFDTVAMLRGEMFVFKGRWFWRVRHNRVLDNYPMPIGHFWRGLPGDIS
AAYERQDGRFVFFKGDRYWLFREANLEPGYPQPLTSYGLGIPYDRIDTAIWWEPTGHTFF
FQEDRYWRFNEETQRGDPGYPKPISVWQGIPASPKGAFLSNDAAYTYFYKGTKYWKFDNE
RLRMEPGYPKSILRDFMGCQEHVEPGPRWPDVARPPFNPHGGAEPGADSAEGDVGDGDGD
FGAGVNKDGGSRVVVQMEEVARTVNVVMVLVPLLLLLCVLGLTYALVQMQRKGAPRVLLY
CKRSLQEWV

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
1-41

# Drug_Target_12_Specific_Function:
Endopeptidase that degrades various components of the extracellular matrix. May activate progelatinase A

# Drug_Target_12_SwissProt_ID:
P51511

# Drug_Target_12_SwissProt_Name:
MMP15_HUMAN

# Drug_Target_12_Synonyms:
MMP-15
MT-MMP 2
MT2-MMP
MT2MMP
MTMMP2
Membrane-type matrix metalloproteinase 2
Membrane-type-2 matrix metalloproteinase
SMCP-2

# Drug_Target_12_Theoretical_pI:
7.49

# Drug_Target_12_Transmembrane_Regions:
626-646

# Drug_Target_13_Cellular_Location:
Isoform Long:Cell membrane
single-pass type I membrane protein (Potential). Isoform Short:Secreted

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
MMP16

# Drug_Target_13_GenBank_ID_Gene:
AB009303

# Drug_Target_13_GenBank_ID_Protein:
2662306

# Drug_Target_13_GeneCard_ID:
MMP16

# Drug_Target_13_Gene_Name:
MMP16

# Drug_Target_13_Gene_Sequence:
>1824 bp
ATGATCTTACTCACATTCAGCACTGGAAGACGGTTGGATTTCGTGCATCATTCGGGGGTG
TTTTTCTTGCAAACCTTGCTTTGGATTTTATGTGCTACAGTCTGCGGAACGGAGCAGTAT
TTCAATGTGGAGGTTTGGTTACAAAAGTACGGCTACCTTCCACCGACTGACCCCAGAATG
TCAGTGCTGCGCTCTGCAGAGACCATGCAGTCTGCCCTAGCTGCCATGCAGCAGTTCTAT
GGCATTAACATGACAGGAAAAGTGGACAGAAACACAATTGACTGGATGAAGAAGCCCCGA
TGCGGTGTACCTGACCAGACAAGAGGTAGCTCCAAATTTCATATTCGTCGAAAGCGATAT
GCATTGACAGGACAGAAATGGCAGCACAAGCACATCACTTACAGTATAAAGAACGTAACT
CCAAAAGTAGGAGACCCTGAGACTCGTAAAGCTATTCGCCGTGCCTTTGATGTGTGGCAG
AATGTAACTCCTCTGACATTTGAAGAAGTTCCCTACAGTGAATTAGAAAATGGCAAACGT
GATGTGGATATAACCATTATTTTTGCATCTGGTTTCCATGGGGACAGCTCTCCCTTTGAT
GGAGAGGGAGGATTTTTGGCACATGCCTACTTCCCTGGACCAGGAATTGGAGGAGATACC
CATTTTGACTCAGATGAGCCATGGACACTAGGAAATCCTAATCATGATGGAAATGACTTA
TTTCTTGTAGCAGTCCATGAACTGGGACATGCTCTGGGATTGGAGCATTCCAATGACCCC
ACTGCCATCATGGCTCCATTTTACCAGTACATGGAAACAGACAACTTCAAACTACCTAAT
GATGATTTACAGGGCATCCAGAAAATATATGGTCCACCTGACAAGATTCCTCCACCTACA
AGACCTCTACCGACAGTGCCCCCACACCGCTCTATTCCTCCGGCTGACCCAAGGAAAAAT
GACAGGCCAAAACCTCCTCGGCCTCCAACCGGCAGACCCTCCTATCCCGGAGCCAAACCC
AACATCTGTGATGGGAACTTTAACACTCTAGCTATTCTTCGTCGTGAGATGTTTGTTTTC
AAGGACCAGTGGTTTTGGCGAGTGAGAAACAACAGGGTGATGGATGGATACCCAATGCAA
ATTACTTACTTCTGGCGGGGCTTGCCTCCTAGTATCGATGCAGTTTATGAAAATAGCGAC
GGGAATTTTGTGTTCTTTAAAGGTAACAAATATTGGGTGTTCAAGGATACAACTCTTCAA
CCTGGTTACCCTCATGACTTGATAACCCTTGGAAGTGGAATTCCCCCTCATGGTATTGAT
TCAGCCATTTGGTGGGAGGACGTCGGGAAAACCTATTTCTTCAAGGGAGACAGATATTGG
AGATATAGTGAAGAAATGAAAACAATGGACCCTGGCTATCCCAAGCCAATCACAGTCTGG
AAAGGGATCCCTGAATCTCCTCAGGGAGCATTTGTACACAAAGAAAATGGCTTTACGTAT
TTCTACAAAGGAAAGGAGTATTGGAAATTCAACAACCAGATACTCAAGGTAGAACCTGGA
CATCCAAGATCCATCCTCAAGGATTTTATGGGCTGTGATGGACCAACAGACAGAGTTAAA
GAAGGACACAGCCCACCAGATGATGTAGACATTGTCATCAAACTGGACAACACAGCCAGC
ACTGTGAAAGCCATAGCTATTGTCATTCCCTGCATCTTGGCCTTATGCCTCCTTGTATTG
GTTTACACTGTGTTCCAGTTCAAGAGGAAAGGAACACCCCGCCACATACTGTACTGTAAA
CGCTCTATGCAAGAGTGGGTGTGA

# Drug_Target_13_General_Function:
Involved in protease activity

# Drug_Target_13_General_References:
7559440	Takino T, Sato H, Shinagawa A, Seiki M: Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem. 1995 Sep 29;270(39):23013-20.
9092507	Shofuda K, Yasumitsu H, Nishihashi A, Miki K, Miyazaki K: Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. J Biol Chem. 1997 Apr 11;272(15):9749-54.
9396633	Matsumoto S, Katoh M, Saito S, Watanabe T, Masuho Y: Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. Biochim Biophys Acta. 1997 Nov 1;1354(2):159-70.

# Drug_Target_13_HGNC_ID:
HGNC:7162

# Drug_Target_13_HPRD_ID:
03776

# Drug_Target_13_ID:
2970

# Drug_Target_13_Locus:
8q21

# Drug_Target_13_Molecular_Weight:
69522

# Drug_Target_13_Name:
Matrix metalloproteinase-16

# Drug_Target_13_Number_of_Residues:
607

# Drug_Target_13_PDB_ID:
1RM8

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_13_Protein_Sequence:
>Matrix metalloproteinase-16 precursor
MILLTFSTGRRLDFVHHSGVFFLQTLLWILCATVCGTEQYFNVEVWLQKYGYLPPTDPRM
SVLRSAETMQSALAAMQQFYGINMTGKVDRNTIDWMKKPRCGVPDQTRGSSKFHIRRKRY
ALTGQKWQHKHITYSIKNVTPKVGDPETRKAIRRAFDVWQNVTPLTFEEVPYSELENGKR
DVDITIIFASGFHGDSSPFDGEGGFLAHAYFPGPGIGGDTHFDSDEPWTLGNPNHDGNDL
FLVAVHELGHALGLEHSNDPTAIMAPFYQYMETDNFKLPNDDLQGIQKIYGPPDKIPPPT
RPLPTVPPHRSIPPADPRKNDRPKPPRPPTGRPSYPGAKPNICDGNFNTLAILRREMFVF
KDQWFWRVRNNRVMDGYPMQITYFWRGLPPSIDAVYENSDGNFVFFKGNKYWVFKDTTLQ
PGYPHDLITLGSGIPPHGIDSAIWWEDVGKTYFFKGDRYWRYSEEMKTMDPGYPKPITVW
KGIPESPQGAFVHKENGFTYFYKGKEYWKFNNQILKVEPGYPRSILKDFMGCDGPTDRVK
EGHSPPDDVDIVIKLDNTASTVKAIAIVIPCILALCLLVLVYTVFQFKRKGTPRHILYCK
RSMQEWV

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
1-31

# Drug_Target_13_Specific_Function:
Endopeptidase that degrades various components of the extracellular matrix, such as collagen type III and fibronectin. Activates progelatinase A. Involved in the matrix remodeling of blood vessels. The short isoform cleaves fibronectin and also collagen type III, but at lower rate. It has no effect on type I, II, IV and V collagen. However, upon interaction with CSPG4, it may be involved in degradation and invasion of type I collagen by melanoma cells

# Drug_Target_13_SwissProt_ID:
P51512

# Drug_Target_13_SwissProt_Name:
MMP16_HUMAN

# Drug_Target_13_Synonyms:
EC 3.4.24.-
MMP- X2
MMP-16
MT-MMP 3
MT3-MMP
MT3MMP
MTMMP3
Matrix metalloproteinase-16 precursor
Membrane-type matrix metalloproteinase 3
Membrane-type-3 matrix metalloproteinase

# Drug_Target_13_Theoretical_pI:
8.74

# Drug_Target_13_Transmembrane_Regions:
565-585

# Drug_Target_14_Cellular_Location:
Isoform Long:Cell membrane

# Drug_Target_14_Chromosome_Location:
1

# Drug_Target_14_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
AB021225

# Drug_Target_14_GenBank_ID_Protein:
18413635

# Drug_Target_14_GeneCard_ID:
MMP17

# Drug_Target_14_Gene_Name:
MMP17

# Drug_Target_14_Gene_Sequence:
>1821 bp
ATGCGGCGCCGCGCAGCCCGGGGACCCGGCCCGCCGCCCCCAGGGCCCGGACTCTCGCGG
TTGCCGCTGCTGCCGCTGCCGCTGCTGCTGCTGCTGGCGCTGGGGACCCGCGGGGGCTGC
GCCGCGCCCGCACCCGCGCCGCGCGCCGAGGACCTCAGCCTGGGAGTGGAGTGGCTAAGC
AGGTTCGGTTACCTGCCCCCGGCTGACCCCACAACAGGGCAGCTGCAGACGCAAGAGGAG
CTGTCTAAGGCCATCACAGCCATGCAGCAGTTTGGTGGCCTGGAGGCCACCGGCATCCTG
GACGAGGCCACCCTGGCCCTGATGAAAACCCCACGCTGCTCCCTGCCAGACCTCCCTGTC
CTGACCCAGGCTCGCAGGAGACGCCAGGCTCCAGCCCCCACCAAGTGGAACAAGAGGAAC
CTGTCGTGGAGGGTCCGGACGTTCCCACGGGACTCACCACTGGGGCACGACACGGTGCGT
GCACTCATGTACTACGCCCTCAAGGTCTGGAGCGACATTGCGCCCCTGAACTTCCACGAG
GTGGCGGGCAGCACCGCCGACATCCAGATCGACTTCTCCAAGGCCGACCATAACGACGGC
TACCCCTTCGACGGCCCCGGCGGCACCGTGGCCCACGCCTTCTTCCCCGGCCACCACCAC
ACCGCCGGGGACACCCACTTTGACGATGACGAGGCCTGGACCTTCCGCTCCTCGGATGCC
CACGGGATGGACCTGTTTGCAGTGGCTGTCCACGAGTTTGGCCACGCCATTGGGTTAAGC
CATGTGGCCGCTGCACACTCCATCATGCGGCCGTACTACCAGGGCCCGGTGGGTGACCCG
CTGCGCTACGGGCTCCCCTACGAGGACAAGGTGCGCGTCTGGCAGCTGTACGGTGTGCGG
GAGTCTGTGTCTCCCACGGCGCAGCCCGAGGAGCCTCCCCTGCTGCCGGAGCCCCCAGAC
AACCGGTCCAGCGCCCCGCCCAGGAAGGACGTGCCCCACAGATGCAGCACTCACTTTGAC
GCGGTGGCCCAGATCCGCGGTGAAGCTTTCTTCTTCAAAGGCAAGTACTTCTGGCGGCTG
ACGCGGGACCGGCACCTGGTGTCCCTGCAGCCGGCACAGATGCACCGCTTCTGGCGGGGC
CTGCCGCTGCACCTGGACAGCGTGGACGCCGTGTACGAGCGCACCAGCGACCACAAGATC
GTCTTCTTTAAAGGAGACAGGTACTGGGTGTTCAAGGACAATAACGTAGAGGAAGGATAC
CCGCGCCCCGTCTCCGACTTCAGCCTCCCGCCTGGCGGCATCGACGCTGCCTTCTCCTGG
GCCCACAATGACAGGACTTATTTCTTTAAGGACCAGCTGTACTGGCGCTACGATGACCAC
ACGAGGCACATGGACCCCGGCTACCCCGCCCAGAGCCCCCTGTGGAGGGGTGTCCCCAGC
ACGCTGGACGACGCCATGCGCTGGTCCGACGGTGCCTCCTACTTCTTCCGTGGCCAGGAG
TACTGGAAAGTGCTGGATGGCGAGCTGGAGGTGGCACCCGGGTACCCACAGTCCACGGCC
CGGGACTGGCTGGTGTGTGGAGACTCACAGGCCGATGGATCTGTGGCTGCGGGCGTGGAC
GCGGCAGAGGGGCCCCGCGCCCCTCCAGGACAACATGACCAGAGCCGCTCGGAGGACGGT
TACGAGGTCTGCTCATGCACCTCTGGGGCATCCTCTCCCCCGGGGGCCCCAGGCCCACTG
GTGGCTGCCACCATGCTGCTGCTGCTGCCGCCACTGTCACCAGGCGCCCTGTGGACAGCG
GCCCAGGCCCTGACGCTATGA

# Drug_Target_14_General_Function:
Involved in calcium ion binding

# Drug_Target_14_General_References:
10471807	Kajita M, Kinoh H, Ito N, Takamura A, Itoh Y, Okada A, Sato H, Seiki M: Human membrane type-4 matrix metalloproteinase (MT4-MMP) is encoded by a novel major transcript: isolation of complementary DNA clones for human and mouse mt4-mmp transcripts. FEBS Lett. 1999 Sep 3;457(3):353-6.
10543448	Kolkenbrock H, Essers L, Ulbrich N, Will H: Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase. Biol Chem. 1999 Sep;380(9):1103-8.
10551873	Wang Y, Johnson AR, Ye QZ, Dyer RD: Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain. J Biol Chem. 1999 Nov 12;274(46):33043-9.
10567400	Itoh Y, Kajita M, Kinoh H, Mori H, Okada A, Seiki M: Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase. J Biol Chem. 1999 Nov 26;274(48):34260-6.
8640782	Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C: Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 1996 Mar 1;56(5):944-9.

# Drug_Target_14_HGNC_ID:
GNC:7163

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
6193

# Drug_Target_14_Locus:
12q24.3

# Drug_Target_14_Molecular_Weight:
67005.7

# Drug_Target_14_Name:
Matrix metalloproteinase-17

# Drug_Target_14_Number_of_Residues:
606

# Drug_Target_14_PDB_ID:
Not Available

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_14_Protein_Sequence:
>Matrix metalloproteinase-17
MRRRAARGPGPPPPGPGLSRLPLLPLPLLLLLALGTRGGCAAPAPAPRAEDLSLGVEWLS
RFGYLPPADPTTGQLQTQEELSKAITAMQQFGGLEATGILDEATLALMKTPRCSLPDLPV
LTQARRRRQAPAPTKWNKRNLSWRVRTFPRDSPLGHDTVRALMYYALKVWSDIAPLNFHE
VAGSTADIQIDFSKADHNDGYPFDGPGGTVAHAFFPGHHHTAGDTHFDDDEAWTFRSSDA
HGMDLFAVAVHEFGHAIGLSHVAAAHSIMRPYYQGPVGDPLRYGLPYEDKVRVWQLYGVR
ESVSPTAQPEEPPLLPEPPDNRSSAPPRKDVPHRCSTHFDAVAQIRGEAFFFKGKYFWRL
TRDRHLVSLQPAQMHRFWRGLPLHLDSVDAVYERTSDHKIVFFKGDRYWVFKDNNVEEGY
PRPVSDFSLPPGGIDAAFSWAHNDRTYFFKDQLYWRYDDHTRHMDPGYPAQSPLWRGVPS
TLDDAMRWSDGASYFFRGQEYWKVLDGELEVAPGYPQSTARDWLVCGDSQADGSVAAGVD
AAEGPRAPPGQHDQSRSEDGYEVCSCTSGASSPPGAPGPLVAATMLLLLPPLSPGALWTA
AQALTL

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
1-38

# Drug_Target_14_Specific_Function:
Endopeptidase that degrades various components of the extracellular matrix, such as fibrin. May be involved in the activation of membrane-bound precursors of growth factors or inflammatory mediators, such as tumor necrosis factor-alpha. May also be involved in tumoral process. Not obvious if able to proteolytically activate progelatinase A. Does not hydrolyze collagen types I, II, III, IV and V, gelatin, fibronectin, laminin, decorin nor alpha1-antitrypsin

# Drug_Target_14_SwissProt_ID:
Q9ULZ9

# Drug_Target_14_SwissProt_Name:
MMP17_HUMAN

# Drug_Target_14_Synonyms:
MMP-17
MT-MMP 4
MT4-MMP
Membrane-type matrix metalloproteinase 4
Membrane-type-4 matrix metalloproteinase

# Drug_Target_14_Theoretical_pI:
6.55

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Secreted, extracellular space, extracellular matrix (By similarity)

# Drug_Target_15_Chromosome_Location:
1

# Drug_Target_15_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
Y08622

# Drug_Target_15_GenBank_ID_Protein:
1702930

# Drug_Target_15_GeneCard_ID:
MMP19

# Drug_Target_15_Gene_Name:
MMP19

# Drug_Target_15_Gene_Sequence:
>1527 bp
ATGAACTGCCAGCAGCTGTGGCTGGGCTTCCTACTCCCCATGACAGTCTCAGGCCGGGTC
CTGGGGCTTGCAGAGGTGGCGCCCGTGGACTACCTGTCACAATATGGGTACCTACAGAAG
CCTCTAGAAGGATCTAATAACTTCAAGCCAGAAGATATCACCGAGGCTCTGAGAGCTTTT
CAGGAAGCATCTGAACTTCCAGTCTCAGGTCAGCTGGATGATGCCACAAGGGCCCGCATG
AGGCAGCCTCGTTGTGGCCTAGAGGATCCCTTCAACCAGAAGACCCTTAAATACCTGTTG
CTGGGCCGCTGGAGAAAGAAGCACCTGACTTTCCGCATCTTGAACCTGCCCTCCACCCTT
CCACCCCACACAGCCCGGGCAGCCCTGCGTCAAGCCTTCCAGGACTGGAGCAATGTGGCT
CCCTTGACCTTCCAAGAGGTGCAGGCTGGTGCGGCTGACATCCGCCTCTCCTTCCATGGC
CGCCAAAGCTCGTACTGTTCCAATACTTTTGATGGGCCTGGGAGAGTCCTGGCCCATGCC
GACATCCCAGAGCTGGGCAGTGTGCACTTCGACGAAGACGAGTTCTGGACTGAGGGGACC
TACCGTGGGGTGAACCTGCGCATCATTGCAGCCCATGAAGTGGGCCATGCTCTGGGGCTT
GGGCACTCCCGATATTCCCAGGCCCTCATGGCCCCAGTCTACGAGGGCTACCGGCCCCAC
TTTAAGCTGCACCCAGATGATGTGGCAGGGATCCAGGCTCTCTATGGCAAGAAGAGTCCA
GTGATAAGGGATGAGGAAGAAGAAGAGACAGAGCTGCCCACTGTGCCCCCAGTGCCCACA
GAACCCAGTCCCATGCCAGACCCTTGCAGTAGTGAACTGGATGCCATGATGCTGGGGCCC
CGTGGGAAGACCTATGCTTTCAAGGGGGACTATGTGTGGACTGTATCAGATTCAGGACCG
GGCCCCTTGTTCCGAGTGTCTGCCCTTTGGGAGGGGCTCCCCGGAAACCTGGATGCTGCT
GTCTACTCGCCTCGAACACAATGGATTCACTTCTTTAAGGGAGACAAGGTGTGGCGCTAC
ATTAATTTCAAGATGTCTCCTGGCTTCCCCAAGAAGCTGAATAGGTCAGAACCTAACCTG
GATGCAGCTCTCTATTGGCCTCTCAACCAAAAGGTGTTCCTCTTTAAGGGCTCCGGGTAC
TGGCAGTGGGACGAGCTAGCCCGAACTGACTTCAGCAGCTACCCCAAACCAATCAAGGGT
TTGTTTACGGGAGTGCCAAACCAGCCCTCGGCTGCTATGAGTTGGCAAGATGGCCGAGTC
TACTTCTTCAAGGGCAAAGTCTACTGGCGCCTCAACCAGCAGCTTCGAGTAGAGAAAGGC
TATCCCAGAAATATTTCCCACAACTGGATGCACTGTCGTCCCCGGACTATAGACACTACC
CCATCAGGTGGGAATACCACTCCCTCAGGTACGGGCATAACCTTGGATACCACTCTCTCA
GCCACAGAAACCACGTTTGAATACTGA

# Drug_Target_15_General_Function:
Involved in calcium ion binding

# Drug_Target_15_General_References:
10809722	Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B, Lopez-Otin C, Murphy G, Knauper V: Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem. 2000 May 19;275(20):14809-16.
10922468	Stracke JO, Fosang AJ, Last K, Mercuri FA, Pendas AM, Llano E, Perris R, Di Cesare PE, Murphy G, Knauper V: Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 2000 Jul 28;478(1-2):52-6.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
8920941	Cossins J, Dudgeon TJ, Catlin G, Gearing AJ, Clements JM: Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem Biophys Res Commun. 1996 Nov 12;228(2):494-8.
9020145	Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S, Murphy G, Lopez-Otin C: Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem. 1997 Feb 14;272(7):4281-6.
9232430	Kolb C, Mauch S, Peter HH, Krawinkel U, Sedlacek R: The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. Immunol Lett. 1997 Jun 1;57(1-3):83-8.
9562866	Sedlacek R, Mauch S, Kolb B, Schatzlein C, Eibel H, Peter HH, Schmitt J, Krawinkel U: Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology. 1998 Feb;198(4):408-23.

# Drug_Target_15_HGNC_ID:
GNC:7165

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
6194

# Drug_Target_15_Locus:
12q14

# Drug_Target_15_Molecular_Weight:
57356.6

# Drug_Target_15_Name:
Matrix metalloproteinase-19

# Drug_Target_15_Number_of_Residues:
508

# Drug_Target_15_PDB_ID:
Not Available

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_15_Protein_Sequence:
>Matrix metalloproteinase-19
MNCQQLWLGFLLPMTVSGRVLGLAEVAPVDYLSQYGYLQKPLEGSNNFKPEDITEALRAF
QEASELPVSGQLDDATRARMRQPRCGLEDPFNQKTLKYLLLGRWRKKHLTFRILNLPSTL
PPHTARAALRQAFQDWSNVAPLTFQEVQAGAADIRLSFHGRQSSYCSNTFDGPGRVLAHA
DIPELGSVHFDEDEFWTEGTYRGVNLRIIAAHEVGHALGLGHSRYSQALMAPVYEGYRPH
FKLHPDDVAGIQALYGKKSPVIRDEEEEETELPTVPPVPTEPSPMPDPCSSELDAMMLGP
RGKTYAFKGDYVWTVSDSGPGPLFRVSALWEGLPGNLDAAVYSPRTQWIHFFKGDKVWRY
INFKMSPGFPKKLNRVEPNLDAALYWPLNQKVFLFKGSGYWQWDELARTDFSSYPKPIKG
LFTGVPNQPSAAMSWQDGRVYFFKGKVYWRLNQQLRVEKGYPRNISHNWMHCRPRTIDTT
PSGGNTTPSGTGITLDTTLSATETTFEY

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
1-18

# Drug_Target_15_Specific_Function:
Endopeptidase that degrades various components of the extracellular matrix, such as aggrecan and cartilage oligomeric matrix protein (comp), during development, haemostasis and pathological conditions (arthritic disease). May also play a role in neovascularization or angiogenesis. Hydrolyzes collagen type IV, laminin, nidogen, nascin-C isoform, fibronectin, and type I gelatin

# Drug_Target_15_SwissProt_ID:
Q99542

# Drug_Target_15_SwissProt_Name:
MMP19_HUMAN

# Drug_Target_15_Synonyms:
MMP-18
MMP-19
Matrix metalloproteinase RASI

# Drug_Target_15_Theoretical_pI:
7.67

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Secreted, extracellular space, extracellular matrix (By similarity)

# Drug_Target_16_Chromosome_Location:
1

# Drug_Target_16_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
Y12779

# Drug_Target_16_GenBank_ID_Protein:
3005946

# Drug_Target_16_GeneCard_ID:
MMP20

# Drug_Target_16_Gene_Name:
MMP20

# Drug_Target_16_Gene_Sequence:
>1452 bp
ATGAAGGTGCTCCCTGCATCTGGCCTTGCTGTCTTCCTCATCATGGCTTTGAAGTTTTCC
ACTGCAGCCCCCTCCCTAGTTGCAGCCTCCCCCAGGACCTGGAGGAACAACTACCGCCTC
GCACAGGCGTATCTTGACAAATATTACACAAATAAAGAAGGACACCAGATTGGTGAGATG
GTTGCAAGAGGAAGCAATTCCATGATAAGGAAGATTAAGGAGCTACAAGCGTTCTTTGGC
CTCCAAGTCACCGGGAAGTTAGACCAGACCACAATGAACGTGATCAAGAAGCCTCGCTGT
GGAGTTCCTGATGTGGCCAATTATCGCCTCTTCCCTGGTGAACCCAAATGGAAAAAAAAT
ACTTTGACATACAGAATATCTAAATACACACCTTCCATGAGTTCTGTCGAGGTGGACAAA
GCAGTGGAGATGGCCTTGCAGGCCTGGAGTAGCGCCGTCCCTCTGAGCTTTGTCAGAATA
AACTCAGGAGAAGCGGATATTATGATATCTTTTGAAAATGGAGATCACGGGGATTCCTAT
CCATTCGATGGGCCTCGGGGGACTCTAGCCCATGCATTTGCTCCTGGAGAAGGCCTGGGA
GGAGATACACATTTCGACAATCCTGAGAAGTGGACTATGGGAACGAATGGTTTTAATTTG
TTTACCGTTGCTGCTCATGAATTTGGCCATGCCCTGGGCCTGGCCCATTCCACAGACCCA
TCAGCACTGATGTACCCAACTTATAAGTACAAGAATCCCTATGGATTCCACCTCCCCAAA
GATGATGTGAAAGGGATCCAGGCATTATACGGACCTCGGAAAGTATTCCTGGGGAAGCCC
ACTCTGCCCCATGCCCCCCATCACAAGCCATCCATCCCTGACCTCTGTGACTCCAGCTCA
TCCTTTGACGCTGTGACAATGCTGGGGAAGGAGCTCCTGCTCTTCAAGGACCGGATTTTC
TGGAGACGGCAGGTTCACTTGCGGACAGGAATTCGGCCCAGCACTATTACCAGCTCCTTC
CCCCAGCTCATGTCCAATGTGGATGCAGCTTACGAAGTGGCTGAGAGGGGCACTGCTTAC
TTCTTCAAAGGTCCCCACTACTGGATAACAAGAGGATTCCAAATGCAAGGTCCTCCTCGG
ACTATTTATGACTTTGGATTTCCAAGGCACGTGCAGCAAATAGATGCTGCTGTCTACCTC
AGGGAGCCACAGAAGACCCTTTTCTTTGTGGGAGATGAATACTACAGCTACGACGAAAGG
AAAAGGAAAATGGAAAAAGACTATCCAAAGAATACTGAAGAAGAATTTTCAGGAGTAAAT
GGCCAAATCGATGCTGCTGTAGAATTAAATGGCTACATTTACTTCTTTTCAGGACCAAAA
ACATACAAGTATGACACAGAGAAGGAAGATGTGGTTAGTGTGGTGAAATCTAGTTCCTGG
ATTGGTTGCTAA

# Drug_Target_16_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_16_General_References:
10922468	Stracke JO, Fosang AJ, Last K, Mercuri FA, Pendas AM, Llano E, Perris R, Di Cesare PE, Murphy G, Knauper V: Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 2000 Jul 28;478(1-2):52-6.
15744043	Kim JW, Simmer JP, Hart TC, Hart PS, Ramaswami MD, Bartlett JD, Hu JC: MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J Med Genet. 2005 Mar;42(3):271-5.
9398237	Llano E, Pendas AM, Knauper V, Sorsa T, Salo T, Salido E, Murphy G, Simmer JP, Bartlett JD, Lopez-Otin C: Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry. 1997 Dec 9;36(49):15101-8.

# Drug_Target_16_HGNC_ID:
GNC:7167

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
6195

# Drug_Target_16_Locus:
11q22.3

# Drug_Target_16_Molecular_Weight:
54359.4

# Drug_Target_16_Name:
Matrix metalloproteinase-20

# Drug_Target_16_Number_of_Residues:
483

# Drug_Target_16_PDB_ID:
Not Available

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_16_Protein_Sequence:
>Matrix metalloproteinase-20
MKVLPASGLAVFLIMALTFSTAAPSLVAASPRTWRNNYRLAQAYLDKYYTNKEGHQIGEM
VARGSNSMIRKIKELQAFFGLQVTGKLDQTTMNVIKKPRCGVPDVANYRLFPGEPKWKKN
TLTYRISKYTPSMSSVEVDKAVEMALQAWSSAVPLSFVRINSGEADIMISFENGDHGDSY
PFDGPRGTLAHAFAPGEGLGGDTHFDNAEKWTMGTNGFNLFTVAAHEFGHALGLAHSTDP
SALMYPTYKYKNPYGFHLPKDDVKGIQALYGPRKVFLGKPTLPHAPHHKPSIPDLCDSSS
SFDAVTMLGKELLLFKDRIFWRRQVHLRTGIRPSTITSSFPQLMSNVDAAYEVAERGTAY
FFKGPHYWITRGFQMQGPPRTIYDFGFPRHVQQIDAAVYLREPQKTLFFVGDEYYSYDER
KRKMEKDYPKNTEEEFSGVNGQIDAAVELNGYIYFFSGPKTYKYDTEKEDVVSVVKSSSW
IGC

# Drug_Target_16_Reaction:
Not Available

# Drug_Target_16_Signals:
1-22

# Drug_Target_16_Specific_Function:
Degrades amelogenin, the major protein component of the enamel matrix and two of the macromolecules characterizing the cartilage extracellular matrix:aggrecan and the cartilage oligomeric matrix protein (COMP). May play a central role in tooth enamel formation

# Drug_Target_16_SwissProt_ID:
O60882

# Drug_Target_16_SwissProt_Name:
MMP20_HUMAN

# Drug_Target_16_Synonyms:
Enamel metalloproteinase
Enamelysin
MMP-20

# Drug_Target_16_Theoretical_pI:
9.08

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Secreted (Potential)

# Drug_Target_17_Chromosome_Location:
1

# Drug_Target_17_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
AF331526

# Drug_Target_17_GenBank_ID_Protein:
22134532

# Drug_Target_17_GeneCard_ID:
MMP21

# Drug_Target_17_Gene_Name:
MMP21

# Drug_Target_17_Gene_Sequence:
>1710 bp
ATGCTCGCCGCCTCCATCTTCCGTCCGACACTGCTGCTCTGCTGGCTGGCTGCTCCCTGG
CCCACCCAGCCCGAGAGTCTCTTCCACAGCCGGGACCGCTCGGACCTGGAGCCGTCCCCA
CTGCGCCAGGCCAAGCCCATTGCCGACCTCCACGCTGCTCAGCGGTTCCTGTCCAGATAC
GGCTGGTCAGGGGTGTGGGCGGCCTGGGGGCCCAGTCCCGAGGGGCCGCCGGAGACCCCC
AAGGGCGCCGCCCTGGCCGAGGCGGTGCGCAGGTTCCAGCGGGCGAACGCGCTGCCGGCC
AGCGGGGAGCTGGACGCGGCCACCCTAGCGGCCATGAACCGGCCGCGCTGCGGGGTCCCG
GACATGCGCCCACCGCCCCCCTCCGCCCCGCCTTCGCCCCCGGGCCCGCCCCCCAGAGCC
CGCTCCAGGCGCTCCCCGCGGGCGCCGCTGTCCTTGTCCCGGCGGGGTTGGCAGCCCCGG
GGCTACCCCGACGGCGGAGCTGCCCAGGCCTTCTCCAAGAGGACGCTGAGCTGGCGGCTG
CTGGGCGAGGCCCTGAGCAGCCAACTGTCCGTGGCCGACCAGCGGCGCATTGTGGCGCTG
GCCTTCAGGATGTGGAGCGAGGTGACGCCGCTGGACTTCCGCGAGGACCTGGCCGCCCCC
GGGGCCGCGGTCGACATCAAGCTGGGCTTTGGGAGAGGCCGGCACCTGGGCTGTCCGCGG
GCCTTCGATGGGAGCGGGCAGGAGTTTGCACACGCCTGGCGCCTAGGTGACATTCACTTT
GACGACGACGAGCACTTCACACCTCCCACCAGTGACACGGGCATCAGCCTTCTCAAGGTG
GCCGTCCATGAAATTGGCCATGTCCTGGGCTTGCCTCACACCTACAGGACGGGATCCATA
ATGCAACCAAATTACATTCCCCAGGAGCCTGCCTTTGAGTTGGACTGGTCAGACAGGAAA
GCAATTCAAAAGCTGTATGGCTCCTGTGAGGGATCATTTGATACTGCGTTTGACTGGATT
CGCAAAGAGAGAAACCAATATGGAGAGGTGATGGTGAGATTTAGCACATATTTCTTCCGT
AACAGCTGGTACTGGCTTTATGAAAATCGAAACAATAGGACACGCTATGGGGACCCTATC
CAAATCCTCACTGGCTGGCCTGGAATCCCAACACACAACATAGATGCCTTTGTTCACATC
TGGACATGGAAAAGAGATGAACGTTATTTTTTTCAAGGAAATCAATACTGGAGATATGAC
AGTGACAAGGATCAGGCCCTCACAGAAGATGAACAAGGAAAAAGCTATCCCAAATTGATT
TCAGAAGGATTTCCTGGCATCCCAAGTCCCCTAGACACGGCGTTTTATGACCGAAGACAG
AAGTTAATTTACTTCTTCAAGGAGTCCCTTGTATTTGCATTTGATGTCAACAGAAATCGA
GTACTTAATTCTTATCCAAAGAGGATTACTGAAGTTTTTCCAGCAGTAATACCACAAAAT
CATCCTTTCAGAAATATAGATTCCGCTTATTACTCCTATGCATACAACTCCATTTTCTTT
TTCAAAGGCAATGCATACTGGAAGGTAGTTAATGACAAGGACAAACAACAGAATTCCTGG
CTTCCTGCTAATGGCTTATTTCCAAAAAAGTTTATTTCAGAGAAGTGGTTTGATGTTTGT
GACGTCCATATCTCCACACTGAACATGTAA

# Drug_Target_17_General_Function:
Involved in calcium ion binding

# Drug_Target_17_General_References:
12490321	Ahokas K, Lohi J, Lohi H, Elomaa O, Karjalainen-Lindsberg ML, Kere J, Saarialho-Kere U: Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer. Gene. 2002 Nov 13;301(1-2):31-41.
12617721	Marchenko GN, Marchenko ND, Strongin AY: The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J. 2003 Jun 1;372(Pt 2):503-15.
15164054	Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10. Nature. 2004 May 27;429(6990):375-81.

# Drug_Target_17_HGNC_ID:
GNC:14357

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
6196

# Drug_Target_17_Locus:
10q26.13

# Drug_Target_17_Molecular_Weight:
65014.8

# Drug_Target_17_Name:
Matrix metalloproteinase-21

# Drug_Target_17_Number_of_Residues:
569

# Drug_Target_17_PDB_ID:
Not Available

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_17_Protein_Sequence:
>Matrix metalloproteinase-21
MLAASIFRPTLLLCWLAAPWPTQPESLFHSRDRSDLEPSPLRQAKPIADLHAAQRFLSRY
GWSGVWAAWGPSPEGPPETPKGAALAEAVRRFQRANALPASGELDAATLAAMNRPRCGVP
DMRPPPPSAPPSPPGPPPRARSRRSPRAPLSLSRRGWQPRGYPDGGAAQAFSKRTLSWRL
LGEALSSQLSAADQRRIVALAFRMWSEVTPLDFREDLAAPGAAVDIKLGFGRGRHLGCPR
AFDGSGQEFAHAWRLGDIHFDDDEHFTPPTSDTGISLLKVAVHEIGHVLGLPHTYRTGSI
MQPNYIPQEPAFELDWSDRKAIQKLYGSCEGSFDTAFDWIRKERNQYGEVMVRFSTYFFR
NSWYWLYENRNNRTRYGDPIQILTGWPGIPTHNIDAFVHIWTWKRDERYFFQGNQYWRYD
SDKDQALTEDEQGKSYPKLISEGFPGIPSPLDTAFYDRRQKLIYFFKESLVFAFDVNRNR
VLNSYPKRITEVFPAVIPQNHPFRNIDSAYYSYAYNSIFFFKGNAYWKVVNDKDKQQNSW
LPANGLFPKKFISEKWFDVCDVHISTLNM

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
1-24

# Drug_Target_17_Specific_Function:
May have an important and specific function in tumor progression and embryogenesis. Cleaves alpha-1-antitrypsin

# Drug_Target_17_SwissProt_ID:
Q8N119

# Drug_Target_17_SwissProt_Name:
MMP21_HUMAN

# Drug_Target_17_Synonyms:
MMP-21

# Drug_Target_17_Theoretical_pI:
9.42

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Membrane

# Drug_Target_18_Chromosome_Location:
1

# Drug_Target_18_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
AF056200

# Drug_Target_18_GenBank_ID_Protein:
3650496

# Drug_Target_18_GeneCard_ID:
MMP23A

# Drug_Target_18_Gene_Name:
MMP23A

# Drug_Target_18_Gene_Sequence:
>1173 bp
ATGGGCCGCGGGGCCCGTGTCCCCTCGGAGGCCCCGGGGGCAGGCGTCGAGCGCCGCTGG
CTTGGAGCCGCGCTGGTCGCCCTGTGCCTCCTCCCCGCGCTGGTGCTGCTGGCCCGGCTG
GGGGCCCCGGCGGTGCCGGCCTGGAGCGCAGCGCAGGGAGACGTCGCTGCGCTGGGCCTC
TCGGCGGTGCCCCCCACCCGGGTCCCGGGCCCACTGGCCCCCCGCAGACGCCGCTACACA
CTGACTCCAGCCAGGCTGCGCTGGGACCACCTCAACCTCACCTACAGGATCCTCTCCTTC
CCGCGGAACCTGCTGAGCCCGCGGGAGACGCGGCGGGCCCTAGCTGCCGCCTTCCGCATG
TGGAGCGACGTGTCCCCCTTCAGCTTCCGCGAGGTGGCCCCCGAGCAGCCCAGCGACCTC
CGGATAGGCTTCTACCCGATCAACCACACGGACTGCCTGGTCTCCGCGCTGCACCACTGC
TTCGACGGCCCCACGGGGGAGCTGGCCCACGCCTTCTTCCCCCCGCACGGCGGCATCCAC
TTCGACGACAGCGAGTACTGGGTCCTGGGCCCCACGCGCTACAGCTGGAAGAAAGGCGTG
TGGCTCACGGACCTGGTGCACGTGGCGGCCCACGAGATCGGCCACGCGCTGGGCCTGATG
CACTCACAACACGGCCGGGCGCTCATGCACCTGAACGCCACGCTGCGCGGCTGGAAGGCG
TTGTCCCAGGACGAGCTGTGGGGGCTGCACCGGCTCTACGGATGCCTCGACAGGCTGTTC
GTGTGCGCGTCCTGGGCGCGGAGGGGCTTCTGCGACGCTCGCCGGCGGCTCATGAAGAGG
CTCTGCCCCAGCAGCTGCGACTTCTGCTACGAATTCCCCTTCCCCACGGTGGCCACCACC
CCACCGCCCCCCAGGACCAAAACCAGGCTGGTGCCCGAGGGCAGGAACGTGACCTTCCGT
TGCGGCCAGAAGATCCTCCACAAGAAAGGGAAAGTGTACTGGTACAAGGACCAGGAGCCC
CTGGAGTTCTCCTACCCCGGCTACCTGGCCCTGGGCGAGGCGCACCTGAGCATCATCGCC
AACGCCGTCAATGAGGGCACCTACACCTGCGTGGTGCGCCGCCAGCAGCGCGTGCTGACC
ACCTACTCCTGGCGAGTCCGTGTGCGGGGCTGA

# Drug_Target_18_General_Function:
Involved in metalloendopeptidase activity

# Drug_Target_18_General_References:
11328856	Ohnishi J, Ohnishi E, Jin M, Hirano W, Nakane D, Matsui H, Kimura A, Sawa H, Nakayama K, Shibuya H, Nagashima K, Takahashi T: Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase-23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development. Mol Endocrinol. 2001 May;15(5):747-64.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16710414	Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1. Nature. 2006 May 18;441(7091):315-21.
18669648	Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. Epub 2008 Jul 31.
9740677	Gururajan R, Grenet J, Lahti JM, Kidd VJ: Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics. 1998 Aug 15;52(1):101-6.
9988691	Velasco G, Pendas AM, Fueyo A, Knauper V, Murphy G, Lopez-Otin C: Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem. 1999 Feb 19;274(8):4570-6.

# Drug_Target_18_HGNC_ID:
GNC:7170

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
6197

# Drug_Target_18_Locus:
1p36.33

# Drug_Target_18_Molecular_Weight:
43934.4

# Drug_Target_18_Name:
Matrix metalloproteinase-23

# Drug_Target_18_Number_of_Residues:
390

# Drug_Target_18_PDB_ID:
Not Available

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00413	Peptidase_M10
PF01549	ShK

# Drug_Target_18_Protein_Sequence:
>Matrix metalloproteinase-23
MGRGARVPSEAPGAGVERRWLGAALVALCLLPALVLLARLGAPAVPAWSAAQGDVAALGL
SAVPPTRVPGPLAPRRRRYTLTPARLRWDHFNLTYRILSFPRNLLSPRETRRALAAAFRM
WSDVSPFSFREVAPEQPSDLRIGFYPINHTDCLVSALHHCFDGPTGELAHAFFPPHGGIH
FDDSEYWVLGPTRYSWKKGVWLTDLVHVAAHEIGHALGLMHSQHGRALMHLNATLRGWKA
LSQDELWGLHRLYGCLDRLFVCASWARRGFCDARRRLMKRLCPSSCDFCYEFPFPTVATT
PPPPRTKTRLVPEGRNVTFRCGQKILHKKGKVYWYKDQEPLEFSYPGYLALGEAHLSIIA
NAVNEGTYTCVVRRQQRVLTTYSWRVRVRG

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Protease

# Drug_Target_18_SwissProt_ID:
O75900

# Drug_Target_18_SwissProt_Name:
MMP23_HUMAN

# Drug_Target_18_Synonyms:
Femalysin
MIFR-1
MMP-21
MMP-22
MMP-23
Matrix metallopeptidase 21
Matrix metalloprotease 22
Matrix metalloproteinase-23, soluble form

# Drug_Target_18_Theoretical_pI:
10.26

# Drug_Target_18_Transmembrane_Regions:
20-40

# Drug_Target_19_Cellular_Location:
Processed matrix metalloproteinase-24:Secreted, extracellular space, extracellular matrix (By simila

# Drug_Target_19_Chromosome_Location:
2

# Drug_Target_19_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
AF131284

# Drug_Target_19_GenBank_ID_Protein:
5381386

# Drug_Target_19_GeneCard_ID:
MMP24

# Drug_Target_19_Gene_Name:
MMP24

# Drug_Target_19_Gene_Sequence:
>1938 bp
ATGCCGAGGAGCCGGGGCGGCCGCGCCGCGCCGGGGCCGCCGCCGCCGCCGCCGCCGCCG
GGCCAGGCCCCGCGCTGGAGCCGCTGGCGGGTCCCTGGGCGGCTGCTGCTGCTGCTGCTG
CCCGCGCTCTGCTGCCTCCCGGGCGCCGCGCGGGCGGCGGCGGCGGCGGCGGGGGCAGGG
AACCGGGCAGCGGTGGCGGTGGCGGTGGCGCGGGCGGACGAGGCGGAGGCGCCCTTCGCC
GGGCAGAACTGGTTAAAGTCCTATGGCTATCTGCTTCCCTATGACTCACGGGCATCTGCG
CTGCACTCAGCGAAGGCCTTGCAGTCGGCAGTCTCCACTATGCAGCAGTTTTACGGGATC
CCGGTCACCGGTGTGTTGGATCAGACAACGATCGAGTGGATGAAGAAACCCCGATGTGGT
GTCCCTGATCACCCCCACTTAAGCCGTAGGCGGAGAAACAAGCGCTATGCCCTGACTGGA
CAGAAGTGGAGGCAAAAACACATCACCTACAGCATTCACAACTATACCCCAAAAGTGGGT
GAGCTAGACACGCGGAAAGCTATTCGCCAGGCTTTCGATGTGTGGCAGAAGGTGACCCCA
CTGACCTTTGAAGAGGTGCCATACCATGAGATCAAAAGTGACCGGAAGGAGGCAGACATC
ATGATCTTTTTTGCTTCTGGTTTCCATGGCGACAGCTCCCCATTTGATGGAGAAGGGGGA
TTCCTGGCCCATGCCTACTTCCCTGGCCCAGGGATTGGAGGAGACACCCACTTTGACTCC
GATGAGCCATGGACGCTAGGAAATGCCAACCATGACGGGAACGACCTCTTCCTGGTGGCT
GTGCATGAGCTGGGCCACGCGCTGGGACTGGAGCACTCCAGCGACCCCAGCGCCATCATG
GCGCCCTTCTACCAGTACATGGAGACGCACAACTTCAAGCTGCCCCAGGACGATCTCCAG
GGCATCCAGAAGATCTATGGACCCCCAGCCGAGCCTCTGGAGCCCACAAGGCCACTCCCT
ACACTCCCCGTCCGCAGGATCCACTCACCATCGGAGAGGAAACACGAGCGCCAGCCCAGG
CCCCCTCGGCCGCCCCTCGGGGACCGGCCATCCACACCAGGCACCAAACCCAACATCTGT
GACGGCAACTTCAACACAGTGGCCCTCTTCCGGGGCGAGATGTTTGTCTTTAAGGATCGC
TGGTTCTGGCGTCTGCGCAATAACCGAGTGCAGGAGGGCTACCCCATGCAGATCGAGCAG
TTCTGGAAGGGCCTGCCTGCCCGCATCGACGCAGCCTATGAAAGGGCCGATGGGAGATTT
GTCTTCTTCAAAGGTGACAAGTATTGGGTGTTTAAGGAGGTGACGGTGGAGCCTGGGTAC
CCCCACAGCCTGGGGGAGCTGGGCAGCTGTTTGCCCCGTGAAGGCATTGACACAGCTCTG
CGCTGGGAACCTGTGGGCAAGACCTACTTTTTCAAAGGCGAGCGGTACTGGCGCTACAGC
GAGGAGCGGCGGGCCACGGACCCTGGCTACCCTAAGCCCATCACCGTGTGGAAGGGCATT
CCACAGGCTCCCCAAGGAGCCTTCATCAGCAAGGAAGGATATTACACCTATTTCTACAAG
GGCCGGGACTACTGGAAGTTTGACAACCAGAAACTGAGCGTGGAGCCAGGCTACCCGCGC
AACATCCTGCGTGACTGGATGGGCTGCAACCAGAAGGAGGTGGAGCGGCGGAAGGAGCGG
CGGCTGCCCCAGGACGACGTGGACATCATGGTGACCATCAACGATGTGCCGGGCTCCGTG
AACGCCGTGGCCGTGGTCATCCCCTGCATCCTGTCCCTCTGCATCCTGGTGCTGGTCTAC
ACCATCTTCCAGTTCAAGAACAAGACAGGCCCTCAGCCTGTCACCTACTATAAGCGGCCA
GTCCAGGAATGGGTGTGA

# Drug_Target_19_General_Function:
Involved in calcium ion binding

# Drug_Target_19_General_References:
10363975	Llano E, Pendas AM, Freije JP, Nakano A, Knauper V, Murphy G, Lopez-Otin C: Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 1999 Jun 1;59(11):2570-6.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
18187866	Imami K, Sugiyama N, Kyono Y, Tomita M, Ishihama Y: Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column. Anal Sci. 2008 Jan;24(1):161-6.

# Drug_Target_19_HGNC_ID:
GNC:7172

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
6198

# Drug_Target_19_Locus:
20q11.2

# Drug_Target_19_Molecular_Weight:
73230.9

# Drug_Target_19_Name:
Matrix metalloproteinase-24

# Drug_Target_19_Number_of_Residues:
645

# Drug_Target_19_PDB_ID:
Not Available

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_19_Protein_Sequence:
>Matrix metalloproteinase-24
MPRSRGGRAAPGPPPPPPPPGQAPRWSRWRVPGRLLLLLLPALCCLPGAARAAAAAAGAG
NRAAVAVAVARADEAEAPFAGQNWLKSYGYLLPYDSRASALHSAKALQSAVSTMQQFYGI
PVTGVLDQTTIEWMKKPRCGVPDHPHLSRRRRNKRYALTGQKWRQKHITYSIHNYTPKVG
ELDTRKAIRQAFDVWQKVTPLTFEEVPYHEIKSDRKEADIMIFFASGFHGDSSPFDGEGG
FLAHAYFPGPGIGGDTHFDSDEPWTLGNANHDGNDLFLVAVHELGHALGLEHSSDPSAIM
APFYQYMETHNFKLPQDDLQGIQKIYGPPAEPLEPTRPLPTLPVRRIHSPSERKHERQPR
PPRPPLGDRPSTPGTKPNICDGNFNTVALFRGEMFVFKDRWFWRLRNNRVQEGYPMQIEQ
FWKGLPARIDAAYERADGRFVFFKGDKYWVFKEVTVEPGYPHSLGELGSCLPREGIDTAL
RWEPVGKTYFFKGERYWRYSEERRATDPGYPKPITVWKGIPQAPQGAFISKEGYYTYFYK
GRDYWKFDNQKLSVEPGYPRNILRDWMGCNQKEVERRKERRLPQDDVDIMVTINDVPGSV
NAVAVVIPCILSLCILVLVYTIFQFKNKTGPQPVTYYKRPVQEWV

# Drug_Target_19_Reaction:
Not Available

# Drug_Target_19_Signals:
1-52

# Drug_Target_19_Specific_Function:
Activates progelatinase A. May also be a proteoglycanase involved in degradation of proteoglycans, such as dermatan sulfate and chondroitin sulfate proteoglycans. Cleaves partially fibronectin, but not collagen type I, nor laminin (By similarity)

# Drug_Target_19_SwissProt_ID:
Q9Y5R2

# Drug_Target_19_SwissProt_Name:
MMP24_HUMAN

# Drug_Target_19_Synonyms:
MMP-24
MT-MMP 5
MT5-MMP
Membrane-type matrix metalloproteinase 5
Membrane-type-5 matrix metalloproteinase
Processed matrix metalloproteinase-24

# Drug_Target_19_Theoretical_pI:
9.58

# Drug_Target_19_Transmembrane_Regions:
603-623

# Drug_Target_1_Cellular_Location:
Secreted protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
MMP1

# Drug_Target_1_GenBank_ID_Gene:
X54925

# Drug_Target_1_GenBank_ID_Protein:
30126

# Drug_Target_1_GeneCard_ID:
MMP1

# Drug_Target_1_Gene_Name:
MMP1

# Drug_Target_1_Gene_Sequence:
>1410 bp
ATGCACAGCTTTCCTCCACTGCTGCTGCTGCTGTTCTGGGGTGTGGTGTCTCACAGCTTC
CCAGCGACTCTAGAAACACAAGAGCAAGATGTGGACTTAGTCCAGAAATACCTGGAAAAA
TACTACAACCTGAAGAATGATGGGAGGCAAGTTGAAAAGCGGAGAAATAGTGGCCCAGTG
GTTGAAAAATTGAAGCAAATGCAGGAATTCTTTGGGCTGAAAGTGACTGGGAAACCAGAT
GCTGAAACCCTGAAGGTGATGAAGCAGCCCAGATGTGGAGTGCCTGATGTGGCTCAGTTT
GTCCTCACTGAGGGGAACCCTCGCTGGGAGCAAACACATCTGACCTACAGGATTGAAAAT
TACACGCCAGATTTGCCAAGAGCAGATGTGGACCATGCCATTGAGAAAGCCTTCCAACTC
TGGAGTAATGTCACACCTCTGACATTCACCAAGGTCTCTGAGGGTCAAGCAGACATCATG
ATATCTTTTGTCAGGGGAGATCATCGGGACAACTCTCCTTTTGATGGACCTGGAGGAAAT
CTTGCTCATGCTTTTCAACCAGGCCCAGGTATTGGAGGGGATGCTCATTTTGATGAAGAT
GAAAGGTGGACCAACAATTTCAGAGAGTACAACTTACATCGTGTTGCGGCTCATGAACTC
GGCCATTCTCTTGGACTCTCCCATTCTACTGATATCGGGGCTTTGATGTACCCTAGCTAC
ACCTTCAGTGGTGATGTTCAGCTAGCTCAGGATGACATTGATGGCATCCAAGCCATATAT
GGACGTTCCCAAAATCCTGTCCAGCCCATCGGCCCACAAACCCCAAAAGCATGTGACAGT
AAGCTAACCTTTGATGCTATAACTACGATTCGGGGAGAAGTGATGTTCTTTAAAGACAGA
TTCTACATGCGCACAAATCCCTTCTACCCGGAAGTTGAGCTCAATTTCATTTCTGTTTTC
TGGCCACAACTGCCAAATGGGCTTGAAGCTGCTTACGAATTTGCCGACAGAGATGAAGTC
CGGTTTTTCAAAGGGAATAAGTACTGGGCTGTTCAGGGACAGAATGTGCTACACGGATAC
CCCAAGGACATCTACAGCTCCTTTGGCTTCCCTAGAACTGTGAAGCATATCGATGCTGCT
CTTTCTGAGGAAAACACTGGAAAAACCTACTTCTTTGTTGCTAACAAATACTGGAGGTAT
GATGAATATAAACGATCTATGGATCCAGGTTATCCCAAAATGATAGCACATGACTTTCCT
GGAATTGGCCACAAAGTTGATGCAGTTTTCATGAAAGATGGATTTTTCTATTTCTTTCAT
GGAACAAGACAATACAAATTTGATCCTAAAACGAAGAGAATTTTGACTCTCCAGAAAGCT
AATAGCTGGTTCAACTGCAGGAAAAATTGA

# Drug_Target_1_General_Function:
Involved in collagenase activity

# Drug_Target_1_General_References:
2167156	Templeton NS, Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG: Cloning and characterization of human tumor cell interstitial collagenase. Cancer Res. 1990 Sep 1;50(17):5431-7.
2557822	Clark IM, Cawston TE: Fragments of human fibroblast collagenase. Purification and characterization. Biochem J. 1989 Oct 1;263(1):201-6.
3009463	Goldberg GI, Wilhelm SM, Kronberger A, Bauer EA, Grant GA, Eisen AZ: Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem. 1986 May 15;261(14):6600-5.
3027129	Brinckerhoff CE, Ruby PL, Austin SD, Fini ME, White HD: Molecular cloning of human synovial cell collagenase and selection of a single gene from genomic DNA. J Clin Invest. 1987 Feb;79(2):542-6.
3030290	Whitham SE, Murphy G, Angel P, Rahmsdorf HJ, Smith BJ, Lyons A, Harris TJ, Reynolds JJ, Herrlich P, Docherty AJ: Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J. 1986 Dec 15;240(3):913-6.
3032950	McKerrow JH: Human fibroblast collagenase contains an amino acid sequence homologous to the zinc-binding site of Serratia protease. J Biol Chem. 1987 May 5;262(13):5943.
3037355	Angel P, Baumann I, Stein B, Delius H, Rahmsdorf HJ, Herrlich P: 12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region. Mol Cell Biol. 1987 Jun;7(6):2256-66.
7656013	Borkakoti N, Winkler FK, Williams DH, D'Arcy A, Broadhurst MJ, Brown PA, Johnson WH, Murray EJ: Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat Struct Biol. 1994 Feb;1(2):106-10.
8031754	Lovejoy B, Hassell AM, Luther MA, Weigl D, Jordan SR: Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. Biochemistry. 1994 Jul 12;33(27):8207-17.
8090713	Spurlino JC, Smallwood AM, Carlton DD, Banks TM, Vavra KJ, Johnson JS, Cook ER, Falvo J, Wahl RC, Pulvino TA, et al.: 1.56 A structure of mature truncated human fibroblast collagenase. Proteins. 1994 Jun;19(2):98-109.
8278810	Lovejoy B, Cleasby A, Hassell AM, Longley K, Luther MA, Weigl D, McGeehan G, McElroy AB, Drewry D, Lambert MH, et al.: Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science. 1994 Jan 21;263(5145):375-7.
9484219	Moy FJ, Chanda PK, Cosmi S, Pisano MR, Urbano C, Wilhelm J, Powers R: High-resolution solution structure of the inhibitor-free catalytic fragment of human fibroblast collagenase determined by multidimensional NMR. Biochemistry. 1998 Feb 10;37(6):1495-504.

# Drug_Target_1_HGNC_ID:
HGNC:7155

# Drug_Target_1_HPRD_ID:
00384

# Drug_Target_1_ID:
1167

# Drug_Target_1_Locus:
11q22.3

# Drug_Target_1_Molecular_Weight:
54007

# Drug_Target_1_Name:
Interstitial collagenase

# Drug_Target_1_Number_of_Residues:
469

# Drug_Target_1_PDB_ID:
1SU3

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_1_Protein_Sequence:
>Interstitial collagenase precursor
MHSFPPLLLLLFWGVVSHSFPATLETQEQDVDLVQKYLEKYYNLKNDGRQVEKRRNSGPV
VEKLKQMQEFFGLKVTGKPDAETLKVMKQPRCGVPDVAQFVLTEGNPRWEQTHLTYRIEN
YTPDLPRADVDHAIEKAFQLWSNVTPLTFTKVSEGQADIMISFVRGDHRDNSPFDGPGGN
LAHAFQPGPGIGGDAHFDEDERWTNNFREYNLHRVAAHELGHSLGLSHSTDIGALMYPSY
TFSGDVQLAQDDIDGIQAIYGRSQNPVQPIGPQTPKACDSKLTFDAITTIRGEVMFFKDR
FYMRTNPFYPEVELNFISVFWPQLPNGLEAAYEFADRDEVRFFKGNKYWAVQGQNVLHGY
PKDIYSSFGFPRTVKHIDAALSEENTGKTYFFVANKYWRYDEYKRSMDPGYPKMIAHDFP
GIGHKVDAVFMKDGFFYFFHGTRQYKFDPKTKRILTLQKANSWFNCRKN

# Drug_Target_1_Reaction:
Cleavage of the triple helix of collagen at about three-quarters of the length of the molecule from the N-terminus, at Gly775!Ile in the alpha1(I) chain. Cleaves synthetic substrates and alpha-macroglobulins at bonds where P1' is a hydrophobic residue COFACTOR Zinc

# Drug_Target_1_Signals:
1-19

# Drug_Target_1_Specific_Function:
Cleaves collagens of types I, II, and III at one site in the helical domain. Also cleaves collagens of types VII and X. In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat's mediated neurotoxicity

# Drug_Target_1_SwissProt_ID:
P03956

# Drug_Target_1_SwissProt_Name:
MMP1_HUMAN

# Drug_Target_1_Synonyms:
EC 3.4.24.7
Fibroblast collagenase
Interstitial collagenase precursor
MMP-1
Matrix metalloproteinase-1

# Drug_Target_1_Theoretical_pI:
6.97

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Cell membrane

# Drug_Target_20_Chromosome_Location:
1

# Drug_Target_20_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
AJ239053

# Drug_Target_20_GenBank_ID_Protein:
8546817

# Drug_Target_20_GeneCard_ID:
MMP25

# Drug_Target_20_Gene_Name:
MMP25

# Drug_Target_20_Gene_Sequence:
>1689 bp
ATGCGGCTGCGGCTCCGGCTTCTGGCGCTGCTGCTTCTGCTGCTGGCACCGCCCGCGCGC
GCCCCGAAGCCCTCGGCGCAGGACGTGAGCCTGGGCGTGGACTGGCTGACTCGCTATGGT
TACCTGCCGCCACCCCACCCTGCCCAGGCCCAGCTGCAGAGCCCTGAGAAGTTGCGCGAT
GCCATCAAAGTCATGCAGAGGTTCGCGGGGCTGCCGGAGACCGGCCGCATGGACCCAGGG
ACAGTGGCCACCATGCGTAAGCCCCGCTGCTCCCTGCCTGACGTGCTGGGGGTGGCGGGG
CTGGTCAGGCGGCGTCGCCGGTACGCTCTGAGCGGCAGCGTGTGGAAGAAGCGAACCCTG
ACATGGAGGGTACGTTCCTTCCCCCAGAGCTCCCAGCTGAGCCAGGAGACCGTGCGGGTC
CTCATGAGCTATGCCCTGATGGCCTGGGGCATGGAGTCAGGCCTCACATTTCATGAGGTG
GATTCCCCCCAGGGCCAGGAGCCCGACATCCTCATCGACTTTGCCCGCGCCTTCCACCAG
GACAGCTACCCCTTCGACGGGTTGGGGGGCACCCTAGCCCATGCCTTCTTCCCTGGGGAG
CACCCCATCTCCGGGGACACTCACTTTGACGATGAGGAGACCTGGACTTTTGGGTCAAAA
GACGGCGAGGGGACCGACCTGTTTGCCGTGGCTGTCCATGAGTTTGGCCACGCCCTGGGC
CTGGGCCACTCCTCAGCCCCCAACTCCATTATGAGGCCCTTCTACCAGGGTCCGGTGGGC
GACCCTGACAAGTACCGCCTGTCTCAGGATGACCGCGATGGCCTGCAGCAACTCTATGGG
AAGGCGCCCCAAACCCCATATGACAAGCCCACAAGGAAACCCCTGGCTCCTCCGCCCCAG
CCCCCGGCCTCGCCCACACACAGCCCATCCTTCCCCATCCCTGATCGATGTGAGGGCAAT
TTTGACGCCATCGCCAACATCCGAGGGGAAACTTTCTTCTTCAAAGGCCCCTGGTTCTGG
CGCCTCCAGCCCTCCGGACAGCTGGTGTCCCCGCGACCCGCACGGCTGCACCGCTTCTGG
GAGGGGCTGCCCGCCCAGGTGAGGGTGGTGCAGGCCGCCTATGCTCGGCACCGAGACGGC
CGAATCCTCCTCTTTAGCGGGCCCCAGTTCTGGGTGTTCCAGGACCGGCAGCTGGAGGGC
GGGGCGCGGCCGCTCACGGAGCTGGGGCTGCCCCCGGGAGAGGAGGTGGACGCCGTGTTC
TCGTGGCCACAGAACGGGAAGACCTACCTGGTCCGCGGCCGGCAGTACTGGCGCTACGAC
GAGGCGGCGGCGCGCCCGGACCCCGGCTACCCTCGCGACCTGAGCCTCTGGGAAGGCGCG
CCCCCCTCCCCTGACGATGTCACCGTCAGCAACGCAGGTGACACCTACTTCTTCAAGGGC
GCCCACTACTGGCGCTTCCCCAAGAACAGCATCAAGACCGAGCCGGACGCCCCCCAGCCC
ATGGGGCCCAACTGGCTGGACTGCCCCGCCCCGAGCTCTGGTCCCCGCGCCCCCAGGCCC
CCCAAAGCGACCCCCGTGTCCGAAACCTGCGATTGTCAGTGCGAGCTCAACCAGGCCGCA
GGACGTTGGCCTGCTCCCATCCCGCTGCTCCTCTTGCCCCTGCTGGTGGGGGGTGTAGCC
TCCCGCTGA

# Drug_Target_20_General_Function:
Involved in calcium ion binding

# Drug_Target_20_General_References:
10628838	Pei D: Leukolysin/MMP25/MT6-MMP: a novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res. 1999 Dec;9(4):291-303.
10706098	Velasco G, Cal S, Merlos-Suarez A, Ferrando AA, Alvarez S, Nakano A, Arribas J, Lopez-Otin C: Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000 Feb 15;60(4):877-82.
11034316	Kojima S, Itoh Y, Matsumoto S, Masuho Y, Seiki M: Membrane-type 6 matrix metalloproteinase (MT6-MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. FEBS Lett. 2000 Sep 1;480(2-3):142-6.

# Drug_Target_20_HGNC_ID:
GNC:14246

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
6199

# Drug_Target_20_Locus:
16p13.3

# Drug_Target_20_Molecular_Weight:
62553.4

# Drug_Target_20_Name:
Matrix metalloproteinase-25

# Drug_Target_20_Number_of_Residues:
562

# Drug_Target_20_PDB_ID:
Not Available

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_20_Protein_Sequence:
>Matrix metalloproteinase-25
MRLRLRLLALLLLLLAPPARAPKPSAQDVSLGVDWLTRYGYLPPPHPAQAQLQSPEKLRD
AIKVMQRFAGLPETGRMDPGTVATMRKPRCSLPDVLGVAGLVRRRRRYALSGSVWKKRTL
TWRVRSFPQSSQLSQETVRVLMSYALMAWGMESGLTFHEVDSPQGQEPDILIDFARAFHQ
DSYPFDGLGGTLAHAFFPGEHPISGDTHFDDEETWTFGSKDGEGTDLFAVAVHEFGHALG
LGHSSAPNSIMRPFYQGPVGDPDKYRLSQDDRDGLQQLYGKAPQTPYDKPTRKPLAPPPQ
PPASPTHSPSFPIPDRCEGNFDAIANIRGETFFFKGPWFWRLQPSGQLVSPRPARLHRFW
EGLPAQVRVVQAAYARHRDGRILLFSGPQFWVFQDRQLEGGARPLTELGLPPGEEVDAVF
SWPQNGKTYLVRGRQYWRYDEAAARPDPGYPRDLSLWEGAPPSPDDVTVSNAGDTYFFKG
AHYWRFPKNSIKTEPDAPQPMGPNWLDCPAPSSGPRAPRPPKATPVSETCDCQCELNQAA
GRWPAPIPLLLLPLLVGGVASR

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
1-21

# Drug_Target_20_Specific_Function:
May activate progelatinase A

# Drug_Target_20_SwissProt_ID:
Q9NPA2

# Drug_Target_20_SwissProt_Name:
MMP25_HUMAN

# Drug_Target_20_Synonyms:
Leukolysin
MMP-25
MT-MMP 6
MT6-MMP
Membrane-type matrix metalloproteinase 6
Membrane-type-6 matrix metalloproteinase

# Drug_Target_20_Theoretical_pI:
8.72

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Secreted, extracellular space, extracellular matrix

# Drug_Target_21_Chromosome_Location:
1

# Drug_Target_21_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
Not Available

# Drug_Target_21_GenBank_ID_Gene:
AF230354

# Drug_Target_21_GenBank_ID_Protein:
8843950

# Drug_Target_21_GeneCard_ID:
MMP26

# Drug_Target_21_Gene_Name:
MMP26

# Drug_Target_21_Gene_Sequence:
>786 bp
ATGCAGCTCGTCATCTTAAGAGTTACTATCTTCTTGCCCTGGTGTTTCGCCGTTCCAGTG
CCCCCTGCTGCAGACCATAAAGGATGGGACTTTGTTGAGGGCTATTTCCATCAATTTTTC
CTGACCAAGAAGGAGTCGCCACTCCTTACCCAGGAGACACAAACACAGCTCCTGCAACAA
TTCCATCGGAATGGGACAGACCTACTTGACATACAGATGCATGCTCTGCTACACCAGCCC
CACTGTGGGGTGCCTGATGGGTCCGACACCTCCATCTCGCCAGGAAGATGCAAGTGGAAT
AAGCACACTCTAACTTACAGGATTATCAATTACCCACATGATATGAAGCCATCCGCAGTG
AAAGACAGTATATATAATGCAGTTTCCATCTGGAGCAATGTGACCCCTTTGATATTCCAG
CAAGTGCAGAATGGAGATGCAGACATCAAGGTTTCTTTCTGGCAGTGGGCCCATGAAGAT
GGTTGGCCCTTTGATGGGCCAGGTGGTATCTTAGGCCATGCCTTTTTACCAAATTCTGGA
AATCCTGGAGTTGTCCATTTTGACAAGAATGAACACTGGTCAGCTTCAGACACTGGATAT
AATCTGTTCCTGGTTGCAACTCATGAGATTGGGCATTCTTTGGGCCTGCAGCACTCTGGG
AATCAGAGCTCCATAATGTACCCCACTTACTGGTATCACGACCCTAGAACCTTCCAGCTC
AGTGCCGATGATATCCAAAGGATCCAGCATTTGTATGGAGAAAAATGTTCATCTGACATA
CCTTAA

# Drug_Target_21_General_Function:
Involved in calcium ion binding

# Drug_Target_21_General_References:
10801841	Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX: Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J Biol Chem. 2000 Jul 7;275(27):20540-4.
10824119	de Coignac AB, Elson G, Delneste Y, Magistrelli G, Jeannin P, Aubry JP, Berthier O, Schmitt D, Bonnefoy JY, Gauchat JF: Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem. 2000 Jun;267(11):3323-9.
10987280	Uria JA, Lopez-Otin C: Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 2000 Sep 1;60(17):4745-51.
11389678	Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY: Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J. 2001 Jun 15;356(Pt 3):705-18.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.

# Drug_Target_21_HGNC_ID:
GNC:14249

# Drug_Target_21_HPRD_ID:
Not Available

# Drug_Target_21_ID:
6200

# Drug_Target_21_Locus:
11p15

# Drug_Target_21_Molecular_Weight:
29708.3

# Drug_Target_21_Name:
Matrix metalloproteinase-26

# Drug_Target_21_Number_of_Residues:
261

# Drug_Target_21_PDB_ID:
Not Available

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00413	Peptidase_M10

# Drug_Target_21_Protein_Sequence:
>Matrix metalloproteinase-26
MQLVILRVTIFLPWCFAVPVPPAADHKGWDFVEGYFHQFFLTKKESPLLTQETQTQLLQQ
FHRNGTDLLDMQMHALLHQPHCGVPDGSDTSISPGRCKWNKHTLTYRIINYPHDMKPSAV
KDSIYNAVSIWSNVTPLIFQQVQNGDADIKVSFWQWAHEDGWPFDGPGGILGHAFLPNSG
NPGVVHFDKNEHWSASDTGYNLFLVATHEIGHSLGLQHSGNQSSIMYPTYWYHDPRTFQL
SADDIQRIQHLYGEKCSSDIP

# Drug_Target_21_Reaction:
Not Available

# Drug_Target_21_Signals:
1-17

# Drug_Target_21_Specific_Function:
May hydrolyze collagen type IV, fibronectin, fibrinogen, beta-casein, type I gelatin and alpha-1 proteinase inhibitor. Is also able to activates progelatinase B

# Drug_Target_21_SwissProt_ID:
Q9NRE1

# Drug_Target_21_SwissProt_Name:
MMP26_HUMAN

# Drug_Target_21_Synonyms:
Endometase
MMP-26
Matrilysin-2

# Drug_Target_21_Theoretical_pI:
6.45

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Secreted, extracellular space, extracellular matrix (By similarity)

# Drug_Target_22_Chromosome_Location:
1

# Drug_Target_22_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
Not Available

# Drug_Target_22_GenBank_ID_Gene:
AF195192

# Drug_Target_22_GenBank_ID_Protein:
11066090

# Drug_Target_22_GeneCard_ID:
MMP27

# Drug_Target_22_Gene_Name:
MMP27

# Drug_Target_22_Gene_Sequence:
>1542 bp
ATGAAGCGCCTTCTGCTTCTGTTTTTGTTCTTTATAACATTTTCTTCTGCATTTCCCTTA
GTCCGGATGATGGAAAATGAAGAAAATGTGCAACTGGCTCAGGCATATCTCAACCAGTTC
TACTCTCTTGAAATAGAAGGGAATCATCTTGTTCAAAGCAAGAATAGGAGTCTCATAGAT
GACAAAATTCGGGAAATGCAAGCATTTTTTGGATTGACAGTGACTGGAAAACTGGACTCA
AACACCCTTGAGATCATGAAGACACCCAGGTGTGGGGTGCCTGATGTGGGCCAGTATGGC
TACACCCTCCCTGGGTGGAGAAAATACAACCTCACCTACAGAATAATAAACTATACTCCG
GATATGGCACGAGCTGCTGTGGATGAGGCTATCCAAGAAGGTTTAGAAGTGTGGAGCAAA
GTCACTCCACTAAAATTCACCAAGATTTCAAAGGGGATTGCAGACATCATGATTGCCTTT
AGGACTCGAGTCCATGGTCGGTGTCCTCGCTATTTTGATGGTCCCTTGGGAGTGCTTGGC
CATGCCTTTCCTCCTGGTCCGGGTCTGGGTGGTGACACTCATTTTGATGAGGATGAAAAC
TGGACCAAGGATGGAGCAGGATTCAACTTGTTTCTTGTGGCTGCTCATGAATTTGGTCAT
GCACTGGGGCTCTCTCACTCCAATGATCAAACAGCCTTGATGTTCCCAAATTATGTCTCC
CTGGATCCCAGAAAATACCCACTTTCTCAGGATGATATCAATGGAATCCAGTCCATCTAT
GGAGGTCTGCCTAAGGAACCTGCTAAGCCAAAGGAACCCACTATACCCCATGCCTGTGAC
CCTGACTTGACTTTTGACGCTATCACAACTTTCCGCAGAGAAGTAATGTTCTTTAAAGGC
AGGCACCTGTGGAGGATCTATTATGATATCACGGATGTTGAGTTTGAATTAATTGCTTCA
TTCTGGCCATCTCTGCCAGCTGATCTGCAAGCTGCATACGAGAACCCCAGAGATAAGATT
CTGGTTTTTAAAGATGAAAACTTCTGGATGATCAGAGGATATGCTGTCTTGCCAGATTAT
CCCAAATCCATCCATACATTAGGTTTTCCAGGACGTGTGAAGAAAATAGATGCAGCCGTC
TGTGATAAGACCACAAGAAAAACCTACTTCTTTGTGGGCATTTGGTGCTGGAGGTTTGAT
GAAATGACCCAAACCATGGACAAAGGGTTCCCGCAGAGAGTGGTAAAACACTTTCCTGGA
ATCAGTATCCGTGTTGATGCTGCTTTCCAGTACAAAGGATTCTTCTTTTTCAGCCGTGGA
TCAAAGCAATTTGAATACGACATTAAGACAAAGAATATTACCCGAATCATGAGAACTAAT
ACTTGGTTTCAATGCAAAGAACCAAAGAACTCCTCATTTGGTTTTGATATCAACAAGGAA
AAAGCACATTCAGGAGGCATAAAGATATTGTATCATAAGAGTTTAAGCTTGTTTATTTTT
GGTATTGTTCATTTGCTGAAAAACACTTCTATTTATCAATAA

# Drug_Target_22_General_Function:
Involved in calcium ion binding

# Drug_Target_22_General_References:
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.
14506071	Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington CJ, Bourgoin P, Edwards DR, Yong VW: Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003 Dec;126(Pt 12):2738-49. Epub 2003 Sep 23.

# Drug_Target_22_HGNC_ID:
GNC:14250

# Drug_Target_22_HPRD_ID:
Not Available

# Drug_Target_22_ID:
6201

# Drug_Target_22_Locus:
11q24

# Drug_Target_22_Molecular_Weight:
59023.4

# Drug_Target_22_Name:
Matrix metalloproteinase-27

# Drug_Target_22_Number_of_Residues:
513

# Drug_Target_22_PDB_ID:
Not Available

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_22_Protein_Sequence:
>Matrix metalloproteinase-27
MKRLLLLFLFFITFSSAFPLVRMMENEENVQLAQAYLNQFYSLEIEGNHLVQSKNRSLID
DKIREMQAFFGLTVTGKLDSNTLEIMKTPRCGVPDVGQYGYTLPGWRKYNLTYRIINYTP
DMARAAVDEAIQEGLEVWSKVTPLKFTKISKGIADIMIAFRTRVHGRCPRYFDGPLGVLG
HAFPPGPGLGGDTHFDEDENWTKDGAGFNLFLVAAHEFGHALGLSHSNDQTALMFPNYVS
LDPRKYPLSQDDINGIQSIYGGLPKEPAKPKEPTIPHACDPDLTFDAITTFRREVMFFKG
RHLWRIYYDITDVEFELIASFWPSLPADLQAAYENPRDKILVFKDENFWMIRGYAVLPDY
PKSIHTLGFPGRVKKIDAAVCDKTTRKTYFFVGIWCWRFDEMTQTMDKGFPQRVVKHFPG
ISIRVDAAFQYKGFFFFSRGSKQFEYDIKTKNITRIMRTNTWFQCKEPKNSSFGFDINKE
KAHSGGIKILYHKSLSLFIFGIVHLLKNTSIYQ

# Drug_Target_22_Reaction:
Not Available

# Drug_Target_22_Signals:
1-17

# Drug_Target_22_Specific_Function:
Matrix metalloproteinases degrade protein components of the extracellular matrix such as fibronectin, laminin, gelatins and/or collagens (By similarity)

# Drug_Target_22_SwissProt_ID:
Q9H306

# Drug_Target_22_SwissProt_Name:
MMP27_HUMAN

# Drug_Target_22_Synonyms:
MMP-27

# Drug_Target_22_Theoretical_pI:
8.95

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Secreted, extracellular space, extracellular matrix

# Drug_Target_23_Chromosome_Location:
1

# Drug_Target_23_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
Not Available

# Drug_Target_23_GenBank_ID_Gene:
AF315683

# Drug_Target_23_GenBank_ID_Protein:
11935132

# Drug_Target_23_GeneCard_ID:
MMP28

# Drug_Target_23_Gene_Name:
MMP28

# Drug_Target_23_Gene_Sequence:
>1563 bp
ATGGTCGCGCGCGTCGGCCTCCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG
GACGCCCAGCCCGCGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGGCGGAGGCATTCCTA
GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACCTCCACTCGATTCAGC
GATGCCATCAGAGCGTTTCAGTGGGTGTCCCAGCTACCTGTCAGCGGCGTGTTGGACCGC
GCCACCCTGCGCCAGATGACTCGTCCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG
GCCTGGGCTGAGAGGATCAGTGACTTGTTTGCTAGACACCGGACCAAAATGAGGCGTAAG
AAACGCTTTGCAAAGCAAGGTAACAAATGGTACAAGCAGCACCTCTCCTACCGCCTGGTG
AACTGGCCTGAGCATCTGCCGGAGCCGGCAGTTCGGGGCGCCGTGCGCGCCGCCTTCCAG
TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCCGCTGAC
ATCCGGCTCACCTTCTTCCAAGGGGACCACAACGATGGGCTGGGCAATGCCTTTGATGGC
CCAGGGGGCGCCCTGGCGCACGCCTTCCTGCCCCGCCGCGGCGAAGCGCACTTCGACCAA
GATGAGCGCTGGTCCCTGAGCCGCCGCCGCGGGCGCAACCTGTTCGTGGTGCTGGCGCAC
GAGATCGGTCACACGCTTGGCCTCACCCACTCGCCCGCGCCGCGCGCGCTCATGGCGCCC
TACTACAAGAGGCTGGGCCGCGACGCGCTGCTCAGCTGGGACGACGTGCTGGCCGTGCAG
AGCCTGTATGGGAAGCCCCTAGGGGGCTCAGTGGCCGTCCAGCTCCCAGGAAAGCTGTTC
ACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCAGGGC
CCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTAC
ATTTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCGT
CCACTGCAGGAAAGATGGGTCGGGCTGCCCCCCAACATTGAGGCTGCGGCAGTGTCATTG
AATGATGGAGATTTCTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAAG
CCAGTGTGGGGTCTCCCACAGCTGTGCCGGGCAGGGGGCCTGCCCCGCCATCCTGACGCC
GCCCTCTTCTTCCCTCCTCTGCGCCGCCTCATCCTCTTCAAGGGTGCCCGCTACTACGTG
CTGGCCCGAGGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGGA
GGCATCCCTGAGGAGGTCAGCGGCGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCTTC
CGAGATGACCGCTACTGGTGCCTCGACCAGGCCAAACTGCAGGCAACCACCTCGGGCCGC
TGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTTC
TGA

# Drug_Target_23_General_Function:
Involved in calcium ion binding

# Drug_Target_23_General_References:
11121398	Lohi J, Wilson CL, Roby JD, Parks WC: Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 2001 Mar 30;276(13):10134-44. Epub 2000 Dec 19.
11255011	Marchenko GN, Strongin AY: MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene. 2001 Mar 7;265(1-2):87-93.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_23_HGNC_ID:
GNC:14366

# Drug_Target_23_HPRD_ID:
Not Available

# Drug_Target_23_ID:
6202

# Drug_Target_23_Locus:
17q11-q21.1

# Drug_Target_23_Molecular_Weight:
58938.5

# Drug_Target_23_Name:
Matrix metalloproteinase-28

# Drug_Target_23_Number_of_Residues:
520

# Drug_Target_23_PDB_ID:
Not Available

# Drug_Target_23_Pathway:
Not Available

# Drug_Target_23_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_23_Protein_Sequence:
>Matrix metalloproteinase-28
MVARVGLLLRALQLLLWGHLDAQPAERGGQELRKEAEAFLEKYGYLNEQVPKAPTSTRFS
DAIRAFQWVSQLPVSGVLDRATLRQMTRPRCGVTDTNSYAAWAERISDLFARHRTKMRRK
KRFAKQGNKWYKQHLSYRLVNWPEHLPEPAVRGAVRAAFQLWSNVSALEFWEAPATGPAD
IRLTFFQGDHNDGLGNAFDGPGGALAHAFLPRRGEAHFDQDERWSLSRRRGRNLFVVLAH
EIGHTLGLTHSPAPRALMAPYYKRLGRDALLSWDDVLAVQSLYGKPLGGSVAVQLPGKLF
TDFETWDSYSPQGRRPETQGPKYCHSSFDAITVDRQQQLYIFKGSHFWEVAADGNVSEPR
PLQERWVGLPPNIEAAAVSLNDGDFYFFKGGRCWRFRGPKPVWGLPQLCRAGGLPRHPDA
ALFFPPLRRLILFKGARYYVLARGGLQVEPYYPRSLQDWGGIPEEVSGALPRPDGSIIFF
RDDRYWRLDQAKLQATTSGRWATELPWMGCWHANSGSALF

# Drug_Target_23_Reaction:
Not Available

# Drug_Target_23_Signals:
1-22

# Drug_Target_23_Specific_Function:
Can degrade casein. Could play a role in tissues homeostasis and repair

# Drug_Target_23_SwissProt_ID:
Q9H239

# Drug_Target_23_SwissProt_Name:
MMP28_HUMAN

# Drug_Target_23_Synonyms:
Epilysin
MMP-28

# Drug_Target_23_Theoretical_pI:
10.07

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10460642	Treharne GD, Boyle JR, Goodall S, Loftus IM, Bell PR, Thompson MM: Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg. 1999 Aug;86(8):1053-8.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
11790786	Bernardo MM, Brown S, Li ZH, Fridman R, Mobashery S: Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem. 2002 Mar 29;277(13):11201-7. Epub 2002 Jan 14.
12527923	Shinoda K, Shibuya M, Hibino S, Ono Y, Matsuda K, Takemura A, Zou D, Kokubo Y, Takechi A, Kudoh S: A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line. Int J Oncol. 2003 Feb;22(2):281-8.
15056115	Fanchon S, Bourd K, Septier D, Everts V, Beertsen W, Menashi S, Goldberg M: Involvement of matrix metalloproteinases in the onset of dentin mineralization. Eur J Oral Sci. 2004 Apr;112(2):171-6.
15748894	Bourd-Boittin K, Fridman R, Fanchon S, Septier D, Goldberg M, Menashi S: Matrix metalloproteinase inhibition impairs the processing, formation and mineralization of dental tissues during mouse molar development. Exp Cell Res. 2005 Apr 1;304(2):493-505. Epub 2005 Jan 11.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
MMP2

# Drug_Target_2_GenBank_ID_Gene:
J03210

# Drug_Target_2_GenBank_ID_Protein:
180671

# Drug_Target_2_GeneCard_ID:
MMP2

# Drug_Target_2_Gene_Name:
MMP2

# Drug_Target_2_Gene_Sequence:
>1936 bp
CCTCTGTCTCCTGGGCTGCCTGCTGAGCCACGCCGCCGCCGCGCCGTCGCCCATCATCAA
GTTCCCCGGCGATGTCGCCCCCAAAACGGACAAAGAGTTGGCAGTGCAATACCTGAACAC
CTTCTATGGCTGCCCCAAGGAGAGCTGCAACCTGTTTGTGCTGAAGGACACACTAAAGAA
GATGCAGAAGTTCTTTGGACTGCCCCAGACAGGTGATCTTGACCAGAATACCATCGAGAC
CATGCGGAAGCCACGCTGCGGCAACCCAGATGTGGCCAACTACAACTTCTTCCCTCGCAA
GCCCAAGTGGGACAAGAACCAGATCACATACAGGATCATCGGCTACACACCTGATCTGGA
CCCAGAGACAGTGGATGATGCCTTTGCTCGTGCCTTCCAAGTCTGGAGCGATGTGACCCC
ACTGCGGTTTTCTCGAATCCATGATGGAGAGGCAGACATCATGATCAACTTTGGCCGCTG
GGAGCATGGCGATGGATACCCCTTTGACGGTAAGGACGGACTCCTGGCTCATGCCTTCGC
CCCAGGCACTGGTGTTGGGGGAGACTCCCATTTTGATGACGATGAGCTATGGACCTTGGG
AGAAGGCCAAGTGGTCCGTGTGAAGTATGGGAACGCCGATGGGGAGTACTGCAAGTTCCC
CTTCTTGTTCAATGGCAAGGAGTACAACAGCTGCACTGATACTGGCCGCAGCGATGGCTT
CCTCTGGTGCTCCACCACCTACAACTTTGAGAAGGATGGCAAGTACGGCTTCTGTCCCCA
TGAAGCCCTGTTCACCATGGGCGGCAACGCTGAAGGACAGCCCTGCAAGTTTCCATTCCG
CTTCCAGGGCACATCCTATGACAGCTGCACCACTGAGGGCCGCACGGATGGCTACCGCTG
GTGCGGCACCACTGAGGACTACGACCGCGACAAGAAGTATGGCTTCTGCCCTGAGACCGC
CATGTCCACTGTTGGTGGGAACTCAGAAGGTGCCCCCTGTGTCTTCCCCTTCACTTTCCT
GGGCAACAAATATGAGAGCTGCACCAGCGCCGGCCGCAGTGACGGAAAGATGTGGTGTGC
GACCACAGCCAACTACGATGACGACCGCAAGTGGGGCTTCTGCCCTGACCAAGGGTACAG
CCTGTTCCTCGTGGCAGCCCACGAGTTTGGCCACGCCATGGGGCTGGAGCACTCCCAAGA
CCCTGGGGCCCTGATGGCACCCATTTACACCTACACCAAGAACTTCCGTCTGTCCCAGGA
TGACATCAAGGGCATTCAGGAGCTCTATGGGGCCTCTCCTGACATTGACCTTGGCACCGG
CCCCACCCCCACACTGGGCCCTGTCACTCCTGAGATCTGCAAACAGGACATTGTATTTGA
TGGCATCGCTCAGATCCGTGGTGAGATCTTCTTCTTCAAGGACCGGTTCATTTGGCGGAC
TGTGACGCCACGTGACAAGCCCATGGGGCCCCTGCTGGTGGCCACATTCTGGCCTGAGCT
CCCGGAAAAGATTGATGCGGTATACGAGGCCCCACAGGAGGAGAAGGCTGTGTTCTTTGC
AGGGAATGAATACTGGATCTACTCAGCCAGCACCTTGGAGCGAGGGTACCCCAAGCCACT
GACCAGCCTGGGACTGCCCCCTGATGTCCAGCGAGTGGATGCCGCCTTTAACTGGAGCAA
AAACAAGAAGACATACATCTTTGCTGGAGACAAATTCTGGAGATACAATGAGGTGAAGAA
GAAAATGGATCCTGGCTTCCCCAAGCTCATCGCAGATGCCTGGAATGCCATCCCCGATAA
CCTGGATGCCGTCGTGGACCTGCAGGGCGGCGGTCACAGCTACTTCTTCAAGGGTGCCTA
TTACCTGAAGCTGGAGAACCAAAGTCTGAAGAGCGTGAAGTTTGGAAGCATCAAATCCGA
CTGGCTAGGCTGCTGA

# Drug_Target_2_General_Function:
Involved in tissue proteolysis activity

# Drug_Target_2_General_References:
12879005	Takino T, Koshikawa N, Miyamori H, Tanaka M, Sasaki T, Okada Y, Seiki M, Sato H: Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene. 2003 Jul 24;22(30):4617-26.
1851724	Collier IE, Bruns GA, Goldberg GI, Gerhard DS: On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes. Genomics. 1991 Mar;9(3):429-34.
2158484	Huhtala P, Eddy RL, Fan YS, Byers MG, Shows TB, Tryggvason K: Completion of the primary structure of the human type IV collagenase preproenzyme and assignment of the gene (CLG4) to the q21 region of chromosome 16. Genomics. 1990 Mar;6(3):554-9.
2162831	Huhtala P, Chow LT, Tryggvason K: Structure of the human type IV collagenase gene. J Biol Chem. 1990 Jul 5;265(19):11077-82.
2834383	Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, He CS, Bauer EA, Goldberg GI: H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem. 1988 May 15;263(14):6579-87.
7583664	Libson AM, Gittis AG, Collier IE, Marmer BL, Goldberg GI, Lattman EE: Crystal structure of the haemopexin-like C-terminal domain of gelatinase A. Nat Struct Biol. 1995 Nov;2(11):938-42.
8549817	Gohlke U, Gomis-Ruth FX, Crabbe T, Murphy G, Docherty AJ, Bode W: The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett. 1996 Jan 8;378(2):126-30.

# Drug_Target_2_HGNC_ID:
HGNC:7166

# Drug_Target_2_HPRD_ID:
00386

# Drug_Target_2_ID:
707

# Drug_Target_2_Locus:
16q13-q21

# Drug_Target_2_Molecular_Weight:
73883

# Drug_Target_2_Name:
72 kDa type IV collagenase

# Drug_Target_2_Number_of_Residues:
660

# Drug_Target_2_PDB_ID:
1GXD

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00040	fn2
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_2_Protein_Sequence:
>72 kDa type IV collagenase precursor
MEALMARGALTGPLRALCLLGCLLSHAAAAPSPIIKFPGDVAPKTDKELAVQYLNTFYGC
PKESCNLFVLKDTLKKMQKFFGLPQTGDLDQNTIETMRKPRCGNPDVANYNFFPRKPKWD
KNQITYRIIGYTPDLDPETVDDAFARAFQVWSDVTPLRFSRIHDGEADIMINFGRWEHGD
GYPFDGKDGLLAHAFAPGTGVGGDSHFDDDELWTLGEGQVVRVKYGNADGEYCKFPFLFN
GKEYNSCTDTGRSDGFLWCSTTYNFEKDGKYGFCPHEALFTMGGNAEGQPCKFPFRFQGT
SYDSCTTEGRTDGYRWCGTTEDYDRDKKYGFCPETAMSTVGGNSEGAPCVFPFTFLGNKY
ESCTSAGRSDGKMWCATTANYDDDRKWGFCPDQGYSLFLVAAHEFGHAMGLEHSQDPGAL
MAPIYTYTKNFRLSQDDIKGIQELYGASPDIDLGTGPTPTLGPVTPEICKQDIVFDGIAQ
IRGEIFFFKDRFIWRTVTPRDKPMGPLLVATFWPELPEKIDAVYEAPQEEKAVFFAGNEY
WIYSASTLERGYPKPLTSLGLPPDVQRVDAAFNWSKNKKTYIFAGDKFWRYNEVKKKMDP
GFPKLIADAWNAIPDNLDAVVDLQGGGHSYFFKGAYYLKLENQSLKSVKFGSIKSDWLGC

# Drug_Target_2_Reaction:
Cleavage of gelatin type I and collagen types IV, V, VII, X. Cleaves the collagen-like sequence Pro-Gln-Gly!Ile-Ala-Gly-Gln

# Drug_Target_2_Signals:
1-29

# Drug_Target_2_Specific_Function:
In addition to gelatin and collagens, it cleaves KiSS1 at a Gly-|-Leu bond

# Drug_Target_2_SwissProt_ID:
P08253

# Drug_Target_2_SwissProt_Name:
MMP2_HUMAN

# Drug_Target_2_Synonyms:
72 kDa gelatinase
72 kDa type IV collagenase precursor
EC 3.4.24.24
Gelatinase A
MMP-2
Matrix metalloproteinase-2
TBE- 1

# Drug_Target_2_Theoretical_pI:
5.09

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
MMP3

# Drug_Target_3_GenBank_ID_Gene:
X05232

# Drug_Target_3_GenBank_ID_Protein:
36633

# Drug_Target_3_GeneCard_ID:
MMP3

# Drug_Target_3_Gene_Name:
MMP3

# Drug_Target_3_Gene_Sequence:
>1434 bp
ATGAAGAGTCTTCCAATCCTACTGTTGCTGTGCGTGGCAGTTTGCTCAGCCTATCCATTG
GATGGAGCTGCAAGGGGTGAGGACACCAGCATGAACCTTGTTCAGAAATATCTAGAAAAC
TACTACGACCTCAAAAAAGATGTGAAACAGTTTGTTAGGAGAAAGGACAGTGGTCCTGTT
GTTAAAAAAATCCGAGAAATGCAGAAGTTCCTTGGATTGGAGGTGACGGGGAAGCTGGAC
TCCGACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGATGTTGGTCACTTC
AGAACCTTTCCTGGCATCCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAAT
TATACACCAGATTTGCCAAAAGATGCTGTTGATTCTGCTGTTGAGAAAGCTCTGAAAGTC
TGGGAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATG
ATCTCTTTTGCAGTTAGAGAACATGGAGACTTTTACCCTTTTGATGGACCTGGAAATGTT
TTGGCCCATGCCTATGCCCCTGGGCCAGGGATTAATGGAGATGCCCACTTTGATGATGAT
GAACAATGGACAAAGGATACAACAGGGACCAATTTATTTCTCGTTGCTGCTCATGAAATT
GGCCACTCCCTGGGTCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTAT
CACTCACTCACAGACCTGACTCGGTTCCGCCTGTCTCAAGATGATATAAATGGCATTCAG
TCCCTCTATGGACCTCCCCCTGACTCCCCTGAGACCCCCCTGGTACCCACGGAACCTGTC
CCTCCAGAACCTGGGACGCCAGCCAACTGTGATCCTGCTTTGTCCTTTGATGCTGTCAGC
ACTCTGAGGGGAGAAATCCTGATCTTTAAAGACAGGCACTTTTGGCGCAAATCCCTCAGG
AAGCTTGAACCTGAATTGCATTTGATCTCTTCATTTTGGCCATCTCTTCCTTCAGGCGTG
GATGCCGCATATGAAGTTACTAGCAAGGACCTCGTTTTCATTTTTAAAGGAAATCAATTC
TGGGCCATCAGAGGAAATGAGGTACGAGCTGGATACCCAAGAGGCATCCACACCCTAGGT
TTCCCTCCAACCGTGAGGAAAATCGATGCAGCCATTTCTGATAAGGAAAAGAACAAAACA
TATTTCTTTGTAGAGGACAAATACTGGAGATTTGATGAGAAGAGAAATTCCATGGAGCCA
GGCTTTCCCAAGCAAATAGCTGAAGACTTTCCAGGGATTGACTCAAAGATTGATGCTGTT
TTTGAAGAATTTGGGTTCTTTTATTTCTTTACTGGATCTTCACAGTTGGAGTTTGACCCA
AATGCAAAGAAAGTGACACACACTTTGAAGAGTAACAGCTGGCTTAATTGTTGA

# Drug_Target_3_General_Function:
Involved in protease activity

# Drug_Target_3_General_References:
10422833	Pavlovsky AG, Williams MG, Ye QZ, Ortwine DF, Purchase CF 2nd, White AD, Dhanaraj V, Roth BD, Johnson LL, Hupe D, Humblet C, Blundell TL: X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity. Protein Sci. 1999 Jul;8(7):1455-62.
10543949	Chen L, Rydel TJ, Gu F, Dunaway CM, Pikul S, Dunham KM, Barnett BL: Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes. J Mol Biol. 1999 Oct 29;293(3):545-57.
2383557	Nagase H, Enghild JJ, Suzuki K, Salvesen G: Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry. 1990 Jun 19;29(24):5783-9.
3030290	Whitham SE, Murphy G, Angel P, Rahmsdorf HJ, Smith BJ, Lyons A, Harris TJ, Reynolds JJ, Herrlich P, Docherty AJ: Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J. 1986 Dec 15;240(3):913-6.
3360803	Saus J, Quinones S, Otani Y, Nagase H, Harris ED Jr, Kurkinen M: The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem. 1988 May 15;263(14):6742-5.
3477804	Wilhelm SM, Collier IE, Kronberger A, Eisen AZ, Marmer BL, Grant GA, Bauer EA, Goldberg GI: Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6725-9.
7656014	Gooley PR, O'Connell JF, Marcy AI, Cuca GC, Salowe SP, Bush BL, Hermes JD, Esser CK, Hagmann WK, Springer JP, et al.: The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat Struct Biol. 1994 Feb;1(2):111-8.
8535233	Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, Hermes JD, et al.: Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 1995 Oct;4(10):1966-76.
8740360	Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB Jr, Rubin JR, Pavlovsky A, Humblet C, Blundell TL: X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure. 1996 Apr 15;4(4):375-86.
9083493	Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Hagmann WK, et al.: Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. J Med Chem. 1997 Mar 14;40(6):1026-40.
9288970	Gomis-Ruth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W: Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997 Sep 4;389(6646):77-81.
9760240	Li YC, Zhang X, Melton R, Ganu V, Gonnella NC: Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor. Biochemistry. 1998 Oct 6;37(40):14048-56.
9792098	Finzel BC, Baldwin ET, Bryant GL Jr, Hess GF, Wilks JW, Trepod CM, Mott JE, Marshall VP, Petzold GL, Poorman RA, O'Sullivan TJ, Schostarez HJ, Mitchell MA: Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity. Protein Sci. 1998 Oct;7(10):2118-26.
9827994	Stockman BJ, Waldon DJ, Gates JA, Scahill TA, Kloosterman DA, Mizsak SA, Jacobsen EJ, Belonga KL, Mitchell MA, Mao B, Petke JD, Goodman L, Powers EA, Ledbetter SR, Kaytes PS, Vogeli G, Marshall VP, Petzold GL, Poorman RA: Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Sci. 1998 Nov;7(11):2281-6.

# Drug_Target_3_HGNC_ID:
HGNC:7173

# Drug_Target_3_HPRD_ID:
01703

# Drug_Target_3_ID:
1926

# Drug_Target_3_Locus:
11q22.3

# Drug_Target_3_Molecular_Weight:
53978

# Drug_Target_3_Name:
Stromelysin-1

# Drug_Target_3_Number_of_Residues:
477

# Drug_Target_3_PDB_ID:
1SLM

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_3_Protein_Sequence:
>Stromelysin-1 precursor
MKSLPILLLLCVAVCSAYPLDGAARGEDTSMNLVQKYLENYYDLKKDVKQFVRRKDSGPV
VKKIREMQKFLGLEVTGKLDSDTLEVMRKPRCGVPDVGHFRTFPGIPKWRKTHLTYRIVN
YTPDLPKDAVDSAVEKALKVWEEVTPLTFSRLYEGEADIMISFAVREHGDFYPFDGPGNV
LAHAYAPGPGINGDAHFDDDEQWTKDTTGTNLFLVAAHEIGHSLGLFHSANTEALMYPLY
HSLTDLTRFRLSQDDINGIQSLYGPPPDSPETPLVPTEPVPPEPGTPANCDPALSFDAVS
TLRGEILIFKDRHFWRKSLRKLEPELHLISSFWPSLPSGVDAAYEVTSKDLVFIFKGNQF
WAIRGNEVRAGYPRGIHTLGFPPTVRKIDAAISDKEKNKTYFFVEDKYWRFDEKRNSMEP
GFPKQIAEDFPGIDSKIDAVFEEFGFFYFFTGSSQLEFDPNAKKVTHTLKSNSWLNC

# Drug_Target_3_Reaction:
Preferential cleavage where P1', P2' and P3' are hydrophobic residues

# Drug_Target_3_Signals:
1-17

# Drug_Target_3_Specific_Function:
Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase

# Drug_Target_3_SwissProt_ID:
P08254

# Drug_Target_3_SwissProt_Name:
MMP3_HUMAN

# Drug_Target_3_Synonyms:
EC 3.4.24.17
MMP-3
Matrix metalloproteinase-3
SL-1
Stromelysin-1 precursor
Transin-1

# Drug_Target_3_Theoretical_pI:
6.07

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Secreted, extracellular space, extracellular matrix (Probable)

# Drug_Target_4_Chromosome_Location:
1

# Drug_Target_4_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
X07819

# Drug_Target_4_GenBank_ID_Protein:
35799

# Drug_Target_4_GeneCard_ID:
MMP7

# Drug_Target_4_Gene_Name:
MMP7

# Drug_Target_4_Gene_Sequence:
>804 bp
ATGCGACTCACCGTGCTGTGTGCTGTGTGCCTGCTGCCTGGCAGCCTGGCCCTGCCGCTG
CCTCAGGAGGCGGGAGGCATGAGTGAGCTACAGTGGGAACAGGCTCAGGACTATCTCAAG
AGATTTTATCTCTATGACTCAGAAACAAAAAATGCCAACAGTTTAGAAGCCAAACTCAAG
GAGATGCAAAAATTCTTTGGCCTACCTATAACTGGAATGTTAAACTCCCGCGTCATAGAA
ATAATGCAGAAGCCCAGATGTGGAGTGCCAGATGTTGCAGAATACTCACTATTTCCAAAT
AGCCCAAAATGGACTTCCAAAGTGGTCACCTACAGGATCGTATCATATACTCGAGACTTA
CCGCATATTACAGTGGATCGATTAGTGTCAAAGGCTTTAAACATGTGGGGCAAAGAGATC
CCCCTGCATTTCAGGAAAGTTGTATGGGGAACTGCTGACATCATGATTGGCTTTGCGCGA
GGAGCTCATGGGGACTCCTACCCATTTGATGGGCCAGGAAACACGCTGGCTCATGCCTTT
GCGCCTGGGACAGGTCTCGGAGGAGATGCTCACTTCGATGAGGATGAACGCTGGACGGAT
GGTAGCAGTCTAGGGATTAACTTCCTGTATGCTGCAACTCATGAACTTGGCCATTCTTTG
GGTATGGGACATTCCTCTGATCCTAATGCAGTGATGTATCCAACCTATGGAAATGGAGAT
CCCCAAAATTTTAAACTTTCCCAGGATGATATTAAAGGCATTCAGAAACTATATGGAAAG
AGAAGTAATTCAAGAAAGAAATAG

# Drug_Target_4_General_Function:
Involved in calcium ion binding

# Drug_Target_4_General_References:
1497627	Marti HP, McNeil L, Thomas G, Davies M, Lovett DH: Molecular characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as PUMP-1. Biochem J. 1992 Aug 1;285 ( Pt 3):899-905.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
2253219	Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H, Umeda M: Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res. 1990 Dec 15;50(24):7758-64.
2550050	Quantin B, Murphy G, Breathnach R: Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry. 1989 Jun 27;28(13):5327-34.
2844164	Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R: The collagenase gene family in humans consists of at least four members. Biochem J. 1988 Jul 1;253(1):187-92.
7756291	Browner MF, Smith WW, Castelhano AL: Matrilysin-inhibitor complexes: common themes among metalloproteases. Biochemistry. 1995 May 23;34(20):6602-10.
8294454	Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH, Matrisian LM: Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem. 1994 Jan 21;269(3):2032-40.

# Drug_Target_4_HGNC_ID:
GNC:7174

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6189

# Drug_Target_4_Locus:
11q21-q22

# Drug_Target_4_Molecular_Weight:
29676.6

# Drug_Target_4_Name:
Matrilysin

# Drug_Target_4_Number_of_Residues:
267

# Drug_Target_4_PDB_ID:
1MMR

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_4_Protein_Sequence:
>Matrilysin
MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLK
EMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDL
PHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAF
APGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGD
PQNFKLSQDDIKGIQKLYGKRSNSRKK

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-17

# Drug_Target_4_Specific_Function:
Degrades casein, gelatins of types I, III, IV, and V, and fibronectin. Activates procollagenase

# Drug_Target_4_SwissProt_ID:
P09237

# Drug_Target_4_SwissProt_Name:
MMP7_HUMAN

# Drug_Target_4_Synonyms:
MMP-7
Matrin
Matrix metalloproteinase-7
Pump-1 protease
Uterine metalloproteinase

# Drug_Target_4_Theoretical_pI:
8.09

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasmic granule. Note=Stored in intracellular granules

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
MMP8

# Drug_Target_5_GenBank_ID_Gene:
J05556

# Drug_Target_5_GenBank_ID_Protein:
180618

# Drug_Target_5_GeneCard_ID:
MMP8

# Drug_Target_5_Gene_Name:
MMP8

# Drug_Target_5_Gene_Sequence:
>1404 bp
ATGTTCTCCCTGAAGACGCTTCCATTTCTGCTCTTACTCCATGTGCAGATTTCCAAGGCC
TTTCCTGTATCTTCTAAAGAGAAAAATACAAAAACTGTTCAGGACTACCTGGAAAAGTTC
TACCAATTACCAAGCAACCAGTATCAGTCTACAAGGAAGAATGGCACTAATGTGATCGTT
GAAAAGCTTAAAGAAATGCAGCGATTTTTTGGGTTGAATGTGACGGGGAAGCCAAATGAG
GAAACTCTGGACATGATGAAAAAGCCTCGCTGTGGAGTGCCTGACAGTGGTGGTTTTATG
TTAACCCCAGGAAACCCCAAGTGGGAACGCACTAACTTGACCTACAGGATTCGAAACTAT
ACCCCACAGCTGTCAGAGGCTGAGGTAGAAAGAGCTATCAAGGATGCCTTTGAACTCTGG
AGTGTTGCATCACCTCTCATCTTCACCAGGATCTCACAGGGAGAGGCAGATATCAACATT
GCTTTTTACCAAAGAGATCACGGTGACAATTCTCCATTTGATGGACCCAATGGAATCCTT
GCTCATGCCTTTCAGCCAGGCCAAGGTATTGGAGGAGATGCTCATTTTGATGCCGAAGAA
ACATGGACCAACACCTCCGCAAATTACAACTTGTTTCTTGTTGCTGCTCATGAATTTGGC
CATTCTTTGGGGCTCGCTCACTCCTCTGACCCTGGTGCCTTGATGTATCCCAACTATGCT
TTCAGGGAAACCAGCAACTACTCACTCCCTCAAGATGACATCGATGGCATTCAGGCCATC
TATGGACTTTCAAGCAACCCTATCCAACCTACTGGACCAAGCACACCCAAACCCTGTGAC
CCCAGTTTGACATTTGATGCTATCACCACACTCCGTGGAGAAATACTTTTCTTTAAAGAC
AGGTACTTCTGGAGAAGGCATCCTCAGCTACAAAGAGTCGAAATGAATTTTATTTCTCTA
TTCTGGCCATCCCTTCCAACTGGTATACAGGCTGCTTATGAAGATTTTGACAGAGACCTC
ATTTTCCTATTTAAAGGCAACCAATACTGGGCTCTGAGTGGCTATGATATTCTGCAAGGT
TATCCCAAGGATATATCAAACTATGGCTTCCCCAGCAGCGTCCAAGCAATTGACGCAGCT
GTTTTCTACAGAAGTAAAACATACTTCTTTGTAAATGACCAATTCTGGAGATATGATAAC
CAAAGACAATTCATGGAGCCAGGTTATCCCAAAAGCATATCAGGTGCCTTTCCAGGAATA
GAGAGTAAAGTTGATGCAGTTTTCCAGCAAGAACATTTCTTCCATGTCTTCAGTGGACCA
AGATATTACGCATTTGATCTTATTGCTCAGAGAGTTACCAGAGTTGCAAGAGGCAATAAA
TGGCTTAACTGTAGATATGGCTGA

# Drug_Target_5_General_Function:
Involved in protease activity and collagen degradation

# Drug_Target_5_General_References:
1330697	Blaser J, Triebel S, Reinke H, Tschesche H: Formation of a covalent Hg-Cys-bond during mercurial activation of PMNL procollagenase gives evidence of a cysteine-switch mechanism. FEBS Lett. 1992 Nov 16;313(1):59-61.
1662606	Blaser J, Knauper V, Osthues A, Reinke H, Tschesche H: Mercurial activation of human polymorphonuclear leucocyte procollagenase. Eur J Biochem. 1991 Dec 18;202(3):1223-30.
2159879	Knauper V, Kramer S, Reinke H, Tschesche H: Characterization and activation of procollagenase from human polymorphonuclear leucocytes. N-terminal sequence determination of the proenzyme and various proteolytically activated forms. Eur J Biochem. 1990 Apr 30;189(2):295-300.
2164002	Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, Mainardi CL: Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem. 1990 Jul 15;265(20):11421-4.
2169256	Knauper V, Kramer S, Reinke H, Tschesche H: Partial amino acid sequence of human PMN leukocyte procollagenase. Biol Chem Hoppe Seyler. 1990 May;371 Suppl:295-304.
2169766	Knauper V, Kramer S, Reinke H, Tschesche H: Partial amino-acid sequence of human PMN leukocyte procollagenase. Biol Chem Hoppe Seyler. 1990 Aug;371(8):733.
2176876	Mallya SK, Mookhtiar KA, Gao Y, Brew K, Dioszegi M, Birkedal-Hansen H, Van Wart HE: Characterization of 58-kilodalton human neutrophil collagenase: comparison with human fibroblast collagenase. Biochemistry. 1990 Nov 27;29(47):10628-34.
7656015	Stams T, Spurlino JC, Smith DL, Wahl RC, Ho TF, Qoronfleh MW, Banks TM, Rubin B: Structure of human neutrophil collagenase reveals large S1' specificity pocket. Nat Struct Biol. 1994 Feb;1(2):119-23.
8137810	Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H: The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 1994 Mar 15;13(6):1263-9.
8307185	Reinemer P, Grams F, Huber R, Kleine T, Schnierer S, Piper M, Tschesche H, Bode W: Structural implications for the role of the N terminus in the 'superactivation' of collagenases. A crystallographic study. FEBS Lett. 1994 Jan 31;338(2):227-33.
9249047	Betz M, Huxley P, Davies SJ, Mushtaq Y, Pieper M, Tschesche H, Bode W, Gomis-Ruth FX: 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur J Biochem. 1997 Jul 1;247(1):356-63.
9655333	Brandstetter H, Engh RA, Von Roedern EG, Moroder L, Huber R, Bode W, Grams F: Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data. Protein Sci. 1998 Jun;7(6):1303-9.

# Drug_Target_5_HGNC_ID:
HGNC:7175

# Drug_Target_5_HPRD_ID:
00385

# Drug_Target_5_ID:
2154

# Drug_Target_5_Locus:
11q22.3

# Drug_Target_5_Molecular_Weight:
53413

# Drug_Target_5_Name:
Neutrophil collagenase

# Drug_Target_5_Number_of_Residues:
467

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_5_Protein_Sequence:
>Neutrophil collagenase precursor
MFSLKTLPFLLLLHVQISKAFPVSSKEKNTKTVQDYLEKFYQLPSNQYQSTRKNGTNVIV
EKLKEMQRFFGLNVTGKPNEETLDMMKKPRCGVPDSGGFMLTPGNPKWERTNLTYRIRNY
TPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFYQRDHGDNSPFDGPNGIL
AHAFQPGQGIGGDAHFDAEETWTNTSANYNLFLVAAHEFGHSLGLAHSSDPGALMYPNYA
FRETSNYSLPQDDIDGIQAIYGLSSNPIQPTGPSTPKPCDPSLTFDAITTLRGEILFFKD
RYFWRRHPQLQRVEMNFISLFWPSLPTGIQAAYEDFDRDLIFLFKGNQYWALSGYDILQG
YPKDISNYGFPSSVQAIDAAVFYRSKTYFFVNDQFWRYDNQRQFMEPGYPKSISGAFPGI
ESKVDAVFQQEHFFHVFSGPRYYAFDLIAQRVTRVARGNKWLNCRYG

# Drug_Target_5_Reaction:
Cleavage of interstitial collagens in the triple helical domain. Unlike internal_xref(ec_num(3,4,24,7)), this enzyme cleaves type III collagen more slowly than type I

# Drug_Target_5_Signals:
1-20

# Drug_Target_5_Specific_Function:
Can degrade fibrillar type I, II, and III collagens

# Drug_Target_5_SwissProt_ID:
P22894

# Drug_Target_5_SwissProt_Name:
MMP8_HUMAN

# Drug_Target_5_Synonyms:
EC 3.4.24.34
MMP-8
Matrix metalloproteinase-8
Neutrophil collagenase precursor
PMNL collagenase
PMNL-CL

# Drug_Target_5_Theoretical_pI:
6.86

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasmic

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
12763661	Underwood CK, Min D, Lyons JG, Hambley TW: The interaction of metal ions and Marimastat with matrix metalloproteinase 9. J Inorg Biochem. 2003 Jun 1;95(2-3):165-70.
17234180	Nenan S, Lagente V, Planquois JM, Hitier S, Berna P, Bertrand CP, Boichot E: Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. Epub 2006 Dec 12.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
MMP9

# Drug_Target_6_GenBank_ID_Gene:
J05070

# Drug_Target_6_GenBank_ID_Protein:
177205

# Drug_Target_6_GeneCard_ID:
MMP9

# Drug_Target_6_Gene_Name:
Not Available

# Drug_Target_6_Gene_Sequence:
>2124 bp
ATGAGCCTCTGGCAGCCCCTGGTCCTGGTGCTCCTGGTGCTGGGCTGCTGCTTTGCTGCC
CCCAGACAGCGCCAGTCCACCCTTGTGCTCTTCCCTGGAGACCTGAGAACCAATCTCACC
GACAGGCAGCTGGCAGAGGAATACCTGTACCGCTATGGTTACACTCGGGTGGCAGAGATG
CGTGGAGAGTCGAAATCTCTGGGGCCTGCGCTGCTGCTTCTCCAGAAGCAACTGTCCCTG
CCCGAGACCGGTGAGCTGGATAGCGCCACGCTGAAGGCCATGCGAACCCCACGGTGCGGG
GTCCCAGACCTGGGCAGATTCCAAACCTTTGAGGGCGACCTCAAGTGGCACCACCACAAC
ATCACCTATTGGATCCAAAACTACTCGGAAGACTTGCCGCGGGCGGTGATTGACGACGCC
TTTGCCCGCGCCTTCGCACTGTGGAGCGCGGTGACGCCGCTCACCTTCACTCGCGTGTAC
AGCCGGGACGCAGACATCGTCATCCAGTTTGGTGTCGCGGAGCACGGAGACGGGTATCCC
TTCGACGGGAAGGACGGGCTCCTGGCACACGCCTTTCCTCCTGGCCCCGGCATTCAGGGA
GACGCCCATTTCGACGATGACGAGTTGTGGTCCCTGGGCAAGGGCGTCGTGGTTCCAACT
CGGTTTGGAAACGCAGATGGCGCGGCCTGCCACTTCCCCTTCATCTTCGAGGGCCGCTCC
TACTCTGCCTGCACCACCGACGGTCGCTCCGACGGCTTGCCCTGGTGCAGTACCACGGCC
AACTACGACACCGACGACCGGTTTGGCTTCTGCCCCAGCGAGAGACTCTACACCCGGGAC
GGCAATGCTGATGGGAAACCCTGCCAGTTTCCATTCATCTTCCAAGGCCAATCCTACTCC
GCCTGCACCACGGACGGTCGCTCCGACGGCTACCGCTGGTGCGCCACCACCGCCAACTAC
GACCGGGACAAGCTCTTCGGCTTCTGCCCGACCCGAGCTGACTCGACGGTGATGGGGGGC
AACTCGGCGGGGGAGCTGTGCGTCTTCCCCTTCACTTTCCTGGGTAAGGAGTACTCGACC
TGTACCAGCGAGGGCCGCGGAGATGGGCGCCTCTGGTGCGCTACCACCTCGAACTTTGAC
AGCGACAAGAAGTGGGGCTTCTGCCCGGACCAAGGATACAGTTTGTTCCTCGTGGCGGCG
CATGAGTTCGGCCACGCGCTGGGCTTAGATCATTCCTCAGTGCCGGAGGCGCTCATGTAC
CCTATGTACCGCTTCACTGAGGGGCCCCCCTTGCATAAGGACGACGTGAATGGCATCCGG
CACCTCTATGGTCCTCGCCCTGAACCTGAGCCACGGCCTCCAACCACCACCACACCGCAG
CCCACGGCTCCCCCGACGGTCTGCCCCACCGGACCCCCCACTGTCCACCCCTCAGAGCGC
CCCACAGCTGGCCCCACAGGTCCCCCCTCAGCTGGCCCCACAGGTCCCCCCACTGCTGGC
CCTTCTACGGCCACTACTGTGCCTTTGAGTCCGGTGGACGATGCCTGCAACGTGAACATC
TTCGACGCCATCGCGGAGATTGGGAACCAGCTGTATTTGTTCAAGGATGGGAAGTACTGG
CGATTCTCTGAGGGCAGGGGGAGCCGGCCGCAGGGCCCCTTCCTTATCGCCGACAAGTGG
CCCGCGCTGCCCCGCAAGCTGGACTCGGTCTTTGAGGAGCCGCTCTCCAAGAAGCTTTTC
TTCTTCTCTGGGCGCCAGGTGTGGGTGTACACAGGCGCGTCGGTGCTGGGCCCGAGGCGT
CTGGACAAGCTGGGCCTGGGAGCCGACGTGGCCCAGGTGACCGGGGCCCTCCGGAGTGGC
AGGGGGAAGATGCTGCTGTTCAGCGGGCGGCGCCTCTGGAGGTTCGACGTGAAGGCGCAG
ATGGTGGATCCCCGGAGCGCCAGCGAGGTGGACCGGATGTTCCCCGGGGTGCCTTTGGAC
ACGCACGACGTCTTCCAGTACCGAGAGAAAGCCTATTTCTGCCAGGACCGCTTCTACTGG
CGCGTGAGTTCCCGGAGTGAGTTGAACCAGGTGGACCAAGTGGGCTACGTGACCTATGAC
ATCCTGCAGTGCCCTGAGGACTAG

# Drug_Target_6_General_Function:
Involved in proteolysis and tissue remodeling

# Drug_Target_6_General_References:
10598806	Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S: Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999 Nov;105(5):418-23.
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
12879005	Takino T, Koshikawa N, Miyamori H, Tanaka M, Sasaki T, Okada Y, Seiki M, Sato H: Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene. 2003 Jul 24;22(30):4617-26.
1371271	Ogata Y, Enghild JJ, Nagase H: Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992 Feb 25;267(6):3581-4.
1645657	Masure S, Proost P, Van Damme J, Opdenakker G: Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur J Biochem. 1991 Jun 1;198(2):391-8.
1653055	Van Ranst M, Norga K, Masure S, Proost P, Vandekerckhove F, Auwerx J, Van Damme J, Opdenakker G: The cytokine-protease connection: identification of a 96-kD THP-1 gelatinase and regulation by interleukin-1 and cytokine inducers. Cytokine. 1991 May;3(3):231-9.
1653238	Huhtala P, Tuuttila A, Chow LT, Lohi J, Keski-Oja J, Tryggvason K: Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem. 1991 Sep 5;266(25):16485-90.
1932376	Opdenakker G, Masure S, Grillet B, Van Damme J: Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res. 1991 Aug;10(4):317-24.
2551898	Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI: SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 1989 Oct 15;264(29):17213-21.
7669817	Sang QX, Birkedal-Hansen H, Van Wart HE: Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta. 1995 Sep 6;1251(2):99-108.
8426746	Sato H, Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 1993 Feb;8(2):395-405.

# Drug_Target_6_HGNC_ID:
HGNC:7176

# Drug_Target_6_HPRD_ID:
00387

# Drug_Target_6_ID:
65

# Drug_Target_6_Locus:
20q11.2-q13.1

# Drug_Target_6_Molecular_Weight:
78428

# Drug_Target_6_Name:
Matrix metalloproteinase-9

# Drug_Target_6_Number_of_Residues:
707

# Drug_Target_6_PDB_ID:
1L6J

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00040	fn2
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1
PF04886	PT

# Drug_Target_6_Protein_Sequence:
>Matrix metalloproteinase-9 precursor
MSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEM
RGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHN
ITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYP
FDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRS
YSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFPFIFQGQSYS
ACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYST
CTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMY
PMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSER
PTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYW
RFSEGRGSRPQGPFLIADKWPALPRKLDSVFEEPLSKKLFFFSGRQVWVYTGASVLGPRR
LDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLD
THDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED

# Drug_Target_6_Reaction:
Cleavage of gelatin types I and V and collagen types IV and V COFACTOR Zinc; Metal; Calcium

# Drug_Target_6_Signals:
1-19

# Drug_Target_6_Specific_Function:
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond

# Drug_Target_6_SwissProt_ID:
P14780

# Drug_Target_6_SwissProt_Name:
MMP9_HUMAN

# Drug_Target_6_Synonyms:
92 kDa gelatinase
92 kDa type IV collagenase
EC 3.4.24.35
GELB
Gelatinase B
MMP-9
Matrix metalloproteinase-9 precursor

# Drug_Target_6_Theoretical_pI:
5.92

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Secreted, extracellular space, extracellular matrix (Probable)

# Drug_Target_7_Chromosome_Location:
1

# Drug_Target_7_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
X07820

# Drug_Target_7_GenBank_ID_Protein:
36629

# Drug_Target_7_GeneCard_ID:
MMP10

# Drug_Target_7_Gene_Name:
MMP10

# Drug_Target_7_Gene_Sequence:
>1431 bp
ATGATGCATCTTGCATTCCTTGTGCTGTTGTGTCTGCCAGTCTGCTCTGCCTATCCTCTG
AGTGGGGCAGCAAAAGAGGAGGACTCCAACAAGGATCTTGCCCAGCAATACCTAGAAAAG
TACTACAACCTCGAAAAGGATGTGAAACAGTTTAGAAGAAAGGACAGTAATCTCATTGTT
AAAAAAATCCAAGGAATGCAGAAGTTCCTTGGGTTGGAGGTGACAGGGAAGCTAGACACT
GACACTCTGGAGGTGATGCGCAAGCCCAGGTGTGGAGTTCCTGACGTTGGTCACTTCAGC
TCCTTTCCTGGCATGCCGAAGTGGAGGAAAACCCACCTTACATACAGGATTGTGAATTAT
ACACCAGATTTGCCAAGAGATGCTGTTGATTCTGCCATTGAGAAAGCTCTGAAAGTCTGG
GAAGAGGTGACTCCACTCACATTCTCCAGGCTGTATGAAGGAGAGGCTGATATAATGATC
TCTTTCGCAGTTAAAGAACATGGAGACTTTTACTCTTTTGATGGCCCAGGACACAGTTTG
GCTCATGCCTACCCACCTGGACCTGGGCTTTATGGAGATATTCACTTTGATGATGATGAA
AAATGGACAGAAGATGCATCAGGCACCAATTTATTCCTCGTTGCTGCTCATGAACTTGGC
CACTCCCTGGGGCTCTTTCACTCAGCCAACACTGAAGCTTTGATGTACCCACTCTACAAC
TCATTCACAGAGCTCGCCCAGTTCCGCCTTTCGCAAGATGATGTGAATGGCATTCAGTCT
CTCTACGGACCTCCCCCTGCCTCTACTGAGGAACCCCTGGTGCCCACAAAATCTGTTCCT
TCGGGATCTGAGATGCCAGCCAAGTGTGATCCTGCTTTGTCCTTCGATGCCATCAGCACT
CTGAGGGGAGAATATCTGTTCTTTAAAGACAGATATTTTTGGCGAAGATCCCACTGGAAC
CCTGAACCTGAATTTCATTTGATTTCTGCATTTTGGCCCTCTCTTCCATCATATTTGGAT
GCTGCATATGAAGTTAACAGCAGGGACACCGTTTTTATTTTTAAAGGAAATGAGTTCTGG
GCCATCAGAGGAAATGAGGTACAAGCAGGTTATCCAAGAGGCATCCATACCCTGGGTTTT
CCTCCAACCATAAGGAAAATTGATGCAGCTGTTTCTGACAAGGAAAAGAAGAAAACATAC
TTCTTTGCAGCGGACAAATACTGGAGATTTGATGAAAATAGCCAGTCCATGGAGCAAGGC
TTCCCTAGACTAATAGCTGATGACTTTCCAGGAGTTGAGCCTAAGGTTGATGCTGTATTA
CAGGCATTTGGATTTTTCTACTTCTTCAGTGGATCATCACAGTTTGAGTTTGACCCCAAT
GCCAGGATGGTGACACACATATTAAAGAGTAACAGCTGGTTACATTGCTAG

# Drug_Target_7_General_Function:
Involved in calcium ion binding

# Drug_Target_7_General_References:
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16959974	Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.
2844164	Muller D, Quantin B, Gesnel MC, Millon-Collard R, Abecassis J, Breathnach R: The collagenase gene family in humans consists of at least four members. Biochem J. 1988 Jul 1;253(1):187-92.

# Drug_Target_7_HGNC_ID:
GNC:7156

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
6188

# Drug_Target_7_Locus:
11q22.3

# Drug_Target_7_Molecular_Weight:
54150.7

# Drug_Target_7_Name:
Stromelysin-2

# Drug_Target_7_Number_of_Residues:
476

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_7_Protein_Sequence:
>Stromelysin-2
MMHLAFLVLLCLPVCSAYPLSGAAKEEDSNKDLAQQYLEKYYNLEKDVKQFRRKDSNLIV
KKIQGMQKFLGLEVTGKLDTDTLEVMRKPRCGVPDVGHFSSFPGMPKWRKTHLTYRIVNY
TPDLPRDAVDSAIEKALKVWEEVTPLTFSRLYEGEADIMISFAVKEHGDFYSFDGPGHSL
AHAYPPGPGLYGDIHFDDDEKWTEDASGTNLFLVAAHELGHSLGLFHSANTEALMYPLYN
SFTELAQFRLSQDDVNGIQSLYGPPPASTEEPLVPTKSVPSGSEMPAKCDPALSFDAIST
LRGEYLFFKDRYFWRRSHWNPEPEFHLISAFWPSLPSYLDAAYEVNSRDTVFIFKGNEFW
AIRGNEVQAGYPRGIHTLGFPPTIRKIDAAVSDKEKKKTYFFAADKYWRFDENSQSMEQG
FPRLIADDFPGVEPKVDAVLQAFGFFYFFSGSSQFEFDPNARMVTHILKSNSWLHC

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
1-17

# Drug_Target_7_Specific_Function:
Can degrade fibronectin, gelatins of type I, III, IV, and V; weakly collagens III, IV, and V. Activates procollagenase

# Drug_Target_7_SwissProt_ID:
P09238

# Drug_Target_7_SwissProt_Name:
MMP10_HUMAN

# Drug_Target_7_Synonyms:
MMP-10
Matrix metalloproteinase-10
SL-2
Transin-2

# Drug_Target_7_Theoretical_pI:
5.59

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Secreted, extracellular space, extracellular matrix (Probable)

# Drug_Target_8_Chromosome_Location:
2

# Drug_Target_8_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
X57766

# Drug_Target_8_GenBank_ID_Protein:
456257

# Drug_Target_8_GeneCard_ID:
MMP11

# Drug_Target_8_Gene_Name:
MMP11

# Drug_Target_8_Gene_Sequence:
>1467 bp
ATGGCTCCGGCCGCCTGGCTCCGCAGCGCGGCCGCGCGCGCCCTCCTGCCCCCGATGCTG
CTGCTGCTGCTCCAGCCGCCGCCGCTGCTGGCCCGGGCTCTGCCGCCGGACGTCCACCAC
CTCCATGCCGAGAGGAGGGGGCCACAGCCCTGGCATGCAGCCCTGCCCAGTAGCCCGGCA
CCTGCCCCTGCCACGCAGGAAGCCCCCCGGCCTGCCAGCAGCCTCAGGCCTCCCCGCTGT
GGCGTGCCCGACCCATCTGATGGGCTGAGTGCCCGCAACCGACAGAAGAGGTTCGTGCTT
TCTGGCGGGCGCTGGGAGAAGACGGACCTCACCTACAGGATCCTTCGGTTCCCATGGCAG
TTGGTGCAGGAGCAGGTGCGGCAGACGATGGCAGAGGCCCTAAAGGTATGGAGCGATGTG
ACGCCACTCACCTTTACTGAGGTGCACGAGGGCCGTGCTGACATCATGATCGACTTCGCC
AGGTACTGGCATGGGGACGACCTGCCGTTTGATGGGCCTGGGGGCATCCTGGCCCATGCC
TTCTTCCCCAAGACTCACCGAGAAGGGGATGTCCACTTCGACTATGATGAGACCTGGACT
ATCGGGGATGACCAGGGCACAGACCTGCTGCAGGTGGCAGCCCATGAATTTGGCCACGTG
CTGGGGCTGCAGCACACAACAGCAGCCAAGGCCCTGATGTCCGCCTTCTACACCTTTCGC
TACCCACTGAGTCTCAGCCCAGATGACTGCAGGGGCGTTCAACACCTATATGGCCAGCCC
TGGCCCACTGTCACCTCCAGGACCCCAGCCCTGGGCCCCCAGGCTGGGATAGACACCAAT
GAGATTGCACCGCTGGAGCCAGACGCCCCGCCAGATGCCTGTGAGGCCTCCTTTGACGCG
GTCTCCACCATCCGAGGCGAGCTCTTTTTCTTCAAAGCGGGCTTTGTGTGGCGCCTCCGT
GGGGGCCAGCTGCAGCCCGGCTACCCAGCATTGGCCTCTCGCCACTGGCAGGGACTGCCC
AGCCCTGTGGACGCTGCCTTCGAGGATGCCCAGGGCCACATTTGGTTCTTCCAAGGTGCT
CAGTACTGGGTGTACGACGGTGAAAAGCCAGTCCTGGGCCCCGCACCCCTCACCGAGCTG
GGCCTGGTGAGGTTCCCGGTCCATGCTGCCTTGGTCTGGGGTCCCGAGAAGAACAAGATC
TACTTCTTCCGAGGCAGGGACTACTGGCGTTTCCACCCCAGCACCCGGCGTGTAGACAGT
CCCGTGCCCCGCAGGGCCACTGACTGGAGAGGGGTGCCCTCTGAGATCGACGCTGCCTTC
CAGGATGCTGATGGCTATGCCTACTTCCTGCGCGGCCGCCTCTACTGGAAGTTTGACCCT
GTGAAGGTGAAGGCTCTGGAAGGCTTCCCCCGTCTCGTGGGTCCTGACTTCTTTGGCTGT
GCCGAGCCTGCCAACACTTTCCTCTGA

# Drug_Target_8_General_Function:
Involved in calcium ion binding

# Drug_Target_8_General_References:
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
16959974	Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.
1701851	Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990 Dec 20-27;348(6303):699-704.
7657606	Anglard P, Melot T, Guerin E, Thomas G, Basset P: Structure and promoter characterization of the human stromelysin-3 gene. J Biol Chem. 1995 Sep 1;270(35):20337-44.
7746327	Pei D, Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995 May 18;375(6528):244-7.

# Drug_Target_8_HGNC_ID:
GNC:7157

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
6190

# Drug_Target_8_Locus:
22q11.2|22q11.23

# Drug_Target_8_Molecular_Weight:
54617.5

# Drug_Target_8_Name:
Stromelysin-3

# Drug_Target_8_Number_of_Residues:
488

# Drug_Target_8_PDB_ID:
1HV5

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10

# Drug_Target_8_Protein_Sequence:
>Stromelysin-3
MAPAAWLRSAAARALLPPMLLLLLQPPPLLARALPPDVHHLHAERRGPQPWHAALPSSPA
PAPATQEAPRPASSLRPPRCGVPDPSDGLSARNRQKRFVLSGGRWEKTDLTYRILRFPWQ
LVQEQVRQTMAEALKVWSDVTPLTFTEVHEGRADIMIDFARYWHGDDLPFDGPGGILAHA
FFPKTHREGDVHFDYDETWTIGDDQGTDLLQVAAHEFGHVLGLQHTTAAKALMSAFYTFR
YPLSLSPDDCRGVQHLYGQPWPTVTSRTPALGPQAGIDTNEIAPLEPDAPPDACEASFDA
VSTIRGELFFFKAGFVWRLRGGQLQPGYPALASRHWQGLPSPVDAAFEDAQGHIWFFQGA
QYWVYDGEKPVLGPAPLTELGLVRFPVHAALVWGPEKNKIYFFRGRDYWRFHPSTRRVDS
PVPRRATDWRGVPSEIDAAFQDADGYAYFLRGRLYWKFDPVKVKALEGFPRLVGPDFFGC
AEPANTFL

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-31

# Drug_Target_8_Specific_Function:
May play an important role in the progression of epithelial malignancies

# Drug_Target_8_SwissProt_ID:
P24347

# Drug_Target_8_SwissProt_Name:
MMP11_HUMAN

# Drug_Target_8_Synonyms:
MMP-11
Matrix metalloproteinase-11
SL-3
ST3

# Drug_Target_8_Theoretical_pI:
6.87

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasmic

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
10669951	Belotti D, Paganoni P, Giavazzi R: MMP inhibitors: experimental and clinical studies. Int J Biol Markers. 1999 Oct-Dec;14(4):232-8.
10852638	Heath EI, Grochow LB: Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs. 2000 May;59(5):1043-55.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
MMP12

# Drug_Target_9_GenBank_ID_Gene:
L23808

# Drug_Target_9_GenBank_ID_Protein:
435970

# Drug_Target_9_GeneCard_ID:
MMP12

# Drug_Target_9_Gene_Name:
MMP12

# Drug_Target_9_Gene_Sequence:
>1413 bp
ATGAAGTTTCTTCTAATACTGCTCCTGCAGGCCACTGCTTCTGGAGCTCTTCCCCTGAAC
AGCTCTACAAGCCTGGAAAAAAATAATGTGCTATTTGGTGAGAGATACTTAGAAAAATTT
TATGGCCTTGAGATAAACAAACTTCCAGTGACAAAAATGAAATATAGTGGAAACTTAATG
AAGGAAAAAATCCAAGAAATGCAGCACTTCTTGGGTCTGAAAGTGACCGGGCAACTGGAC
ACATCTACCCTGGAGATGATGCACGCACCTCGATGTGGAGTCCCCGATCTCCATCATTTC
AGGGAAATGCCAGGGGGGCCCGTATGGAGGAAACATTATATCACCTACAGAATCAATAAT
TACACACCTGACATGAACCGTGAGGATGTTGACTACGCAATCCGGAAAGCTTTCCAAGTA
TGGAGTAATGTTACCCCCTTGAAATTCAGCAAGATTAACACAGGCATGGCTGACATTTTG
GTGGTTTTTGCCCGTGGAGCTCATGGAGACTTCCATGCTTTTGATGGCAAAGGTGGAATC
CTAGCCCATGCTTTTGGACCTGGATCTGGCATTGGAGGGGATGCACATTTCGATGAGGAC
GAATTCTGGACTACACATTCAGGAGGCACAAACTTGTTCCTCACTGCTGTTCACGAGATT
GGCCATTCCTTAGGTCTTGGCCATTCTAGTGATCCAAAGGCTGTAATGTTCCCCACCTAC
AAATATGTCGACATCAACACATTTCGCCTCTCTGCTGATGACATACGTGGCATTCAGTCC
CTGTATGGAGACCCAAAAGAGAACCAACGCTTGCCAAATCCTGACAATTCAGAACCAGCT
CTCTGTGACCCCAATTTGAGTTTTGATGCTGTCACTACCGTGGGAAATAAGATCTTTTTC
TTCAAAGACAGGTTCTTCTGGCTGAAGGTTTCTGAGAGACCAAAGACCAGTGTTAATTTA
ATTTCTTCCTTATGGCCAACCTTGCCATCTGGCATTGAAGCTGCTTATGAAATTGAAGCC
AGAAATCAAGTTTTTCTTTTTAAAGATGACAAATACTGGTTAATTAGCAATTTAAGACCA
GAGCCAAATTATCCCAAGAGCATACATTCTTTTGGTTTTCCTAACTTTGTGAAAAAAATT
GATGCAGCTGTTTTTAACCCACGTTTTTATAGGACCTACTTCTTTGTAGATAACCAGTAT
TGGAGGTATGATGAAAGGAGACAGATGATGGACCCTGGTTATCCCAAACTGATTACCAAG
AACTTCCAAGGAATCGGGCCTAAAATTGATGCAGTCTTCTATTCTAAAAACAAATACTAC
TATTTCTTCCAAGGATCTAACCAATTTGAATATGACTTCCTACTCCAACGTATCACCAAA
ACACTGAAAAGCAATAGCTGGTTTGGTTGTTAG

# Drug_Target_9_General_Function:
Involved in protease activity

# Drug_Target_9_General_References:
11575928	Lang R, Kocourek A, Braun M, Tschesche H, Huber R, Bode W, Maskos K: Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. J Mol Biol. 2001 Sep 28;312(4):731-42.
11575929	Nar H, Werle K, Bauer MM, Dollinger H, Jung B: Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J Mol Biol. 2001 Sep 28;312(4):743-51.
8226919	Shapiro SD, Kobayashi DK, Ley TJ: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem. 1993 Nov 15;268(32):23824-9.
9115292	Gronski TJ Jr, Martin RL, Kobayashi DK, Walsh BC, Holman MC, Huber M, Van Wart HE, Shapiro SD: Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem. 1997 May 2;272(18):12189-94.

# Drug_Target_9_HGNC_ID:
HGNC:7158

# Drug_Target_9_HPRD_ID:
03027

# Drug_Target_9_ID:
2203

# Drug_Target_9_Locus:
11q22.3

# Drug_Target_9_Molecular_Weight:
54002

# Drug_Target_9_Name:
Macrophage metalloelastase

# Drug_Target_9_Number_of_Residues:
470

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00045	Hemopexin
PF00413	Peptidase_M10
PF01471	PG_binding_1

# Drug_Target_9_Protein_Sequence:
>Macrophage metalloelastase precursor
MKFLLILLLQATASGALPLNSSTSLEKNNVLFGERYLEKFYGLEINKLPVTKMKYSGNLM
KEKIQEMQHFLGLKVTGQLDTSTLEMMHAPRCGVPDVHHFREMPGGPVWRKHYITYRINN
YTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDFHAFDGKGGI
LAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTY
KYVDINTFRLSADDIRGIQSLYGDPKENQRLPNPDNSEPALCDPNLSFDAVTTVGNKIFF
FKDRFFWLKVSERPKTSVNLISSLWPTLPSGIEAAYEIEARNQVFLFKDDKYWLISNLRP
EPNYPKSIHSFGFPNFVKKIDAAVFNPRFYRTYFFVDNQYWRYDERRQMMDPGYPKLITK
NFQGIGPKIDAVFYSKNKYYYFFQGSNQFEYDFLLQRITKTLKSNSWFGC

# Drug_Target_9_Reaction:
Hydrolysis of soluble and insoluble elastin [1]. Specific cleavages are also produced at -Ala14!Leu- and -Tyr16!Leu- in the B chain of insulin [2]

# Drug_Target_9_Signals:
1-16

# Drug_Target_9_Specific_Function:
May be involved in tissue injury and remodeling. Has significant elastolytic activity. Can accept large and small amino acids at the P1' site, but has a preference for leucine. Aromatic or hydrophobic residues are preferred at the P1 site, with small hydrophobic residues (preferably alanine) occupying P3

# Drug_Target_9_SwissProt_ID:
P39900

# Drug_Target_9_SwissProt_Name:
MMP12_HUMAN

# Drug_Target_9_Synonyms:
EC 3.4.24.65
HME
ME
MMP-12
Macrophage elastase
Macrophage metalloelastase precursor
Matrix metalloproteinase-12

# Drug_Target_9_Theoretical_pI:
8.98

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB00786
